

**EVALUATION OF BACTERIAL AND FUNGAL AGENTS IN THE  
AETIOLOGY OF CHRONIC SUPPURATIVE OTITIS MEDIA WITH  
SPECIAL REFERENCE TO ANTIMICROBIAL RESISTANCE  
PATTERN OF *PSEUDOMONAS SPECIES***

*Dissertation submitted to*  
**THE TAMILNADU DR.M.G.R. MEDICAL UNIVERSITY**

*in partial fulfillment of the regulations  
for the award of the degree of*  
**M.D.(MICROBIOLOGY)**  
**BRANCH-IV**



**MADRAS MEDICAL COLLEGE,**  
**THE TAMILNADU DR.M.G.R. MEDICAL UNIVERSITY**  
**CHENNAI – TAMILNADU**

**APRIL – 2016**

## **CERTIFICATE**

This is to certify that this Dissertation entitled “**EVALUATION OF BACTERIAL AND FUNGAL AGENTS IN THE AETIOLOGY OF CHRONIC SUPPURATIVE OTITIS MEDIA WITH SPECIAL REFERENCE TO ANTIMICROBIAL RESISTANCE PATTERN OF *PSEUDOMONAS SPECIES***” is a bonafide record of work done by **Dr.SANGEETHA BASKARAN**, during the period of her post graduate study from 2013 to 2016 under guidance and supervision in the Institute of Microbiology, Madras Medical College and Rajiv Gandhi Government General Hospital, Chennai – 600 003, in partial fulfillment of the requirement for **M.D.MICROBIOLOGY** degree Examination of The Tamilnadu Dr.M.G.R. Medical University to be held in April 2016.

**DR.R.VIMALA ,M.D.,**  
**Dean**  
Madras Medical College &  
Rajiv Gandhi Government  
General Hospital  
Chennai – 600 003.

**DR.MANGALA ADISESH,M.D.,**  
**Director I/C**  
Institute of Microbiology,  
Madras Medical College,  
Chennai – 600 003.

## DECLARATION

I declare that the dissertation entitled “**EVALUATION OF BACTERIAL AND FUNGAL AGENTS IN THE AETIOLOGY OF CHRONIC SUPPURATIVE OTITIS MEDIA WITH SPECIAL REFERENCE TO ANTIMICROBIAL RESISTANCE PATTERN OF *PSEUDOMONAS SPECIES***” submitted by me for the degree of M.D. is the record work carried out by me during the period of **October 2014 to August 2016** under the guidance of **Prof.Dr.U.UMADEVI M.D.** Professor of Microbiology, Institute of Microbiology, Madras Medical College, Chennai. This dissertation is submitted to the Tamilnadu Dr.M.G.R Medical University, Chennai, in partial fulfillment of the University regulations for the award of degree of M.D. Microbiology (Branch IV) examination to be held in April 2016.

Place : Chennai

Date :

**Signature of the Candidate**

**(Dr.SANGEETHA BASKARAN)**

Signature of the guide

**Prof.Dr.U.UMADEVI MD.,**

Professor,

Institute of Microbiology,

Madras Medical College

## ACKNOWLEDGEMENT

I humbly submit this work to the Almighty who has given the health and ability to pass through all the difficulties in the compilation and proclamation of this blue print.

I wish to express my sincere thanks to our Dean, **Dr.R.VIMALA,M.D.**, for permitting me to use the resources of this institution for my study.

I express my thanks and gratitude to **Prof. Dr. MANGALA ADISESH ,M.D.**,Director I/C and Professor, Institute of Microbiology for her support, invaluable suggestions, erudite guidance in my study and for being a source of inspiration in my endeavours.

My sincere thanks to **Dr.N.MUTHUKUMAR M.S.,HOD.**, & Professor, Upgraded Institute of otorhinolaryngology permitting me to carry out my study.

I express my gratitude to our former Director, **PROF. Dr.G.JAYALAKSHMI, M.D.,DTCD** and former Professors **Dr.T.SHEILA DORIS M.D.**, and **Dr.K.MUTHULAKSHMI M.D.**, and Assistant Professor **,Dr.LATA SRIRAM, M.sc., Ph.D.**,for their guidance and support.

I extend my whole hearted gratitude and heartfelt thanks to my guide, **Prof. Dr.U.UMADEVI M.D.**, for her constant support , helpful suggestions and valuable guidance throughout my study. I feel fortunate to work under her guidance and am thankful for being a source of inspiration in my endeavours.

I would like to thank my Professors **Dr.S.VASANTHI M.D., Dr.S.THASNEEM BANU M.D., Dr. R.VANAJA M.D.,** for their valuable assistance in my study.

I extend my whole hearted gratitude and special thanks to co-guide Assistant Professor **Dr.N. LAKSHMI PRIYA M.D.,** for her valuable guidance and constant support in my study.

I also express my thanks to our Assistant professors **Dr.R.DEEPA M.D., Dr.N.RATHNAPRIYA M.D., Dr. T.USHA KRISHNAN M.D., Dr. DAVID AGATHA M.D.,Dr.N.LAKSHMIPRIYA M.D.,DCH., Dr.K.G.VENKATESH M.D, and Dr.B.NATESAN M.D.,DLO.,** for their immense support in my study.

I hereby express my gratitude to all the technical staff for their help throughout my study.

I would like to thank my department colleagues and friends for their constant support and co-operation.

I would like to thank the Institutional Ethics Committee for approving my study.

Finally I am indebted to my parents **Mr.M.BASKARAN,Bsc,Agri., Mrs.K.LAXMI.M.A,M.Phil.,** my husband **Mr.E.V.PRABHAKARAN, B.E,M.B.A.,** and my son **P.VISHAL** who have been the solid pillars of everlasting support and encouragement and for their heartfelt blessings.

Turnitin Document Viewer - Google Chrome

https://turnitin.com/dv?s=1&o=574948389&u=1041009915&student\_user=1&lang=en\_us&

The Tamil Nadu Dr.M.G.R.Medical ... TNM3RMU EXAMINATIONS - DUE 30-Q...

Originality GraderMark PeerMark

Evaluation of bacterial and fungal agents in the aetiology of chronic suppurative otitis

By SANGEETHA BASUKARAN

turnitin 24% --

SIMILAR OUT OF 0

### 1 INTRODUCTION

Chronic suppurative otitis media is defined as chronic inflammation of middle ear and mastoid cavity that presents with recurrent ear discharge of more than three months duration through a perforated tympanic membrane. (1)

CSOM is a major health problem in developing countries causing serious local damage and threatening complications. It is an important cause of preventable hearing loss in developing countries.

#### Match Overview

1	Prakash, Rajat, Juyal, D...	2%
2	Norberto J. Palleron, "P...	1%
3	www.ayubmed.edu.pk	1%
4	de.slideshare.net	1%
5	27.251.28.59.8080	1%
6	ijobs.com	1%
7	jrm.rsmjournals.com	10%

Open Devices and Printers

Eject v115w

- YASO (G)

Turnitin Document ...html

11:54 AM 9/28/2015

## CONTENTS

S.NO	TITLE	PAGE.NO
1	INTRODUCTION	1
2	AIMS AND OBJECTIVES	2
3	REVIEW OF LITERATURE	3
4	MATERIALS AND METHODS	30
5	RESULTS	43
6	DISCUSSION	64
7	SUMMARY	73
8	CONCLUSION	75
	APPENDIX –I ABBREVIATIONS APPENDIX –II STAINS ,REAGENTS AND MEDIA ANNEXURE –I CERTIFICATE OF APPROVAL ANNEXURE –II PROFORMA ANNEXURE –III PATIENTS CONSENT FORM ANNEXURE –IV MASTER SHEET	
	BIBLIOGRAPHY	

## LIST OF TABLES

S.NO	TITLE	PAGENO.
1	ANALYSIS OF AGE DISTRIBUTION IN CSOM	44
2	ANALYSIS OF GENDER DISTRIBUTION	45
3	DISTRIBUTION OF RISK FACTORS ASSOCIATED WITH CSOM	46
4	DISTRIBUTION OF UNILATERAL AND BILATERAL CSOM	47
5	DISTRIBUTION ACCORDING TO THE TYPE OF CSOM	48
6	ANALYSIS OF CULTURE RESULTS	49
7	MONOMICROBIAL AND POLYMICROBIAL DISTRIBUTION IN CSOM	50
8	MICROBIAL PROFILE	51
9	DISTRIBUTION OF GRAM NEGATIVE ISOLATES IN CSOM	52
10	ANALYSIS OF GRAM POSITIVE ISOLATES IN CSOM	53
11	LIST OF FUNGI ISOLATES IN CSOM	53
12	ISOLATES ON POLYMICROBIAL PROFILE	54



<b>S.NO</b>	<b>TITLE</b>	<b>PAGENO.</b>
13	ANTIMICROBIAL SUSCEPTIBILITY OF BACTERIAL ISOLATES	55
14	ANTIBIOTIC REISTANCE OF BACTERIAL ISOLATES	56
15	ANTIBIOTIC PROFILE OF PSEUDOMONAS AERUGINOSA	57
16	ANTIBIOTIC PROFILE OF STAPHYLOCOCCUS AUREUS	58
17	ANTIMICROBIAL SUSCEPTIBILITY PATTERN OF K. PNEUMONIAE	59
18	ANTIMICROBIAL SUSCEPTIBILITY PATTERN OF E.COLI	60
19	ANTIMICROBIAL SUSCEPTIBILITY PATTERN OF P.MIRABILIS	61
20	ANTIMICROBIAL SUSCEPTIBILITY PATTERN OF A.BAUMANNII	62
21	DETECTION OF ESBL IN P.AERUGINOSA	63
22	DETECTION OF AMPC BETALACTAMASE IN P.AERUGINOSA	63
23	DETECTION OF MBL IN P.AERUGINOSA	63

## LIST OF FIGURES

<b>S.NO</b>	<b>TITLE</b>	<b>PAGENO.</b>
1	ANALYSIS OF AGE DISTRIBUTION IN CSOM	44
2	ANALYSIS OF GENDER DISTRIBUTION	45
3	DISTRIBUTION OF RISK FACRORS ASSOCIATED WITH CSOM	46
4	DISTRIBUTION OF UNILATERAL AND BILATERAL CSOM	47
5	DISTRIBUTION ACCORDING TO THE TYPE OF CSOM	48
6	ANALYSIS OF CULTURE RESULTS	49
7	MICROBIAL PROFILE	51
8	DISTRIBUTION OF GRAM NEGATIVE ISOLATES IN CSOM	52
9	ANALYSIS OF GRAM POSITIVE ISOLATES IN CSOM	53
10	ISOLATES ON POLYMICROBIAL PROFILE	54
11	ANTIBIOTIC PROFILE OF PSEUDOMONAS AERUGINOSA	57

12	ANTIBIOTIC PROFILE OF STAPHYLOCOCCUS AUREUS	58
13	ANTIMICROBIAL SUSCEPTIBILITY PATTERN OF K. PNEUMONIAE	59
14	ANTIMICROBIAL SUSCEPTIBILITY PATTERN OF E.COLI	60
15	ANTIMICROBIAL SUSCEPTIBILITY PATTERN OF P.MIRABILIS	61
16	ANTIMICROBIAL SUSCEPTIBILITY PATTERN OF A.BAUMANNII	62

**TITLE: “EVALUATION OF BACTERIAL AND FUNGAL AGENTS IN THE  
AETIOLOGY OF CHRONIC SUPPURATIVE OTITIS MEDIA WITH  
SPECIAL REFERENCE TO ANTIMICROBIAL RESISTANCE PATTERN  
OF *PSEUDOMONAS SPECIES*”**

**ABSTRACT**

**Introduction:**

Chronic suppurative otitis media is defined as chronic inflammation of middle ear and mastoid cavity that presents with recurrent ear discharge of more than three months duration through a perforated tympanic membrane.

CSOM is a major health problem in developing countries causing serious local damage and threatening complications. It is an important cause of preventable hearing loss in developing countries.

Evaluation of the microbiological agents and their antimicrobial sensitivity pattern in that region is helpful in the initiation of specific therapy and thus minimizing its complications and emergence of resistant strains.

**Aim:**

To determine the microbiological profile and their antimicrobial sensitivity pattern in patients with chronic suppurative otitis media, with special reference to antimicrobial resistance patterns of *Pseudomonas species*.

**Materials and Methods:**

This study was conducted at the Institute of Microbiology ,Madras Medical college, Chennai . A total of 100 patients with clinical diagnosis of CSOM from the Upgraded Institute of Otorhinolaryngology were enrolled in the study and the samples were obtained from each patient using sterile cotton swabs and processed by standard microbiological techniques. Detection of Extended spectrum betalactamases

(ESBL),AmpC betalactamases and Metallo betalactamases in *Pseudomonas* isolates were done by phenotypic methods.

### **Results:**

Analysis of bacterial flora of the present study showed predominance of Gram negative bacilli. The highest incidence was that of *Pseudomonas aeruginosa* (39.6%) followed by *Staphylococcus aureus*(31.68%). In the present study for all the isolates Amikacin was found to be the most effective drug followed by ciprofloxacin and gentamicin. Antimicrobial susceptibility of *Pseudomonas aeruginosa* revealed 100% sensitive to imipenem,97% sensitive to piperazillin-tazobactam,78% to amikacin ,75% to ciprofloxacin , 68% to gentamicin and 46% to ceftazidime.

ESBL producers in *Pseudomonas aeruginosa* was found to be 17.07%,AmpC betalactamase was found in 9.75% .

### **Conclusion:**

The emergence of *P. aeruginosa* possessing combinations of  $\beta$ -lactamases like ESBL and AmpC betalactamases is a major public health concern necessitating efficient detection and intervention to control drug resistance. Hence continuous and periodic evaluation of microbiological pattern and antibiotic sensitivity is essential to reduce the potential risk of complications and emergence of resistant strains.

## INTRODUCTION

Chronic suppurative otitis media is defined as chronic inflammation of middle ear and mastoid cavity that presents with recurrent ear discharge of more than three months duration through a perforated tympanic membrane.<sup>(1)</sup>

CSOM is a major health problem in developing countries causing serious local damage and threatening complications. It is an important cause of preventable hearing loss in developing countries.

Incidence of this disease is higher among people with low socio-economic status because of malnutrition, overcrowding, poor hygiene, inadequate health care, and recurrent upper respiratory tract infection.

It is a massive health problem and India is one of the countries with highest CSOM prevalence (> 4%) where urgent attention is needed.<sup>(1)</sup> It causes conductive and sensorineural hearing loss and has got adverse effect on childhood development.<sup>(2)</sup> It is a common cause of hearing impairment and can occasionally lead to fatal intracranial complications. Hence early and accurate diagnosis of CSOM is life saving.

Both Gram positive and Gram negative bacteria are responsible for infection of the middle ear in addition to fungal etiological agents. Due to advent of newer antibiotics, the microbial organisms and their resistance pattern is changing constantly.

Evaluation of the microbiological agents and their antibiotic sensitivity pattern in that region is helpful in the initiation of specific therapy and thus minimizing its complications and emergence of resistant strains.

Due to the long period of morbidity of CSOM and the repeated occurrences of otorrhea during that period, patients are often prescribed empiric antibiotics in outpatient clinics without microbiologic evaluation. CSOM has received considerable attention not only because of its high incidence and chronicity but also because of issues such as bacterial resistance and ototoxicity with both topical and systemic antibiotics .

The most common microorganisms found in CSOM are *Pseudomonas aeruginosa*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Proteus mirabilis*, *Escherichia coli*, *Aspergillus spp*, *Candida spp* and these vary in different geographical distributions.<sup>(4)</sup> Fungal infections of the middle ear are common as fungi thrive well in moist pus.

Therefore, this study was undertaken to know the pattern of microbes and their antimicrobial susceptibility pattern to provide a guideline for empirical antibiotic therapy.

*Pseudomonas aeruginosa*, one of the most common organism isolated in CSOM is an important cause of nosocomial infection which has developed resistance to many potent antibiotics .Hence the antimicrobial resistance pattern of *Pseudomonas species* was also analysed in this study.

Though the treatment of CSOM is controversial, and subject to change particularly in developing countries, the antibiogram of these organisms have been reported to vary with time and geographical area, probably due to use and abuse of antibiotics. Hence the need for periodic update of antibiogram for effective chemotherapy and management of CSOM cannot be overemphasized.



## **AIMS AND OBJECTIVES**

### **AIMS**

To determine the Microbiological profile and their antimicrobial sensitivity pattern in patients with chronic suppurative otitis media, with special reference to antimicrobial resistance patterns of *Pseudomonas species* .

### **OBJECTIVES**

1. To isolate aerobic bacterial and fungal agents causing CSOM.
2. To identify the antimicrobial susceptibility pattern of the bacterial isolates.
3. To determine the resistance pattern of *Pseudomonas species*
4. To detect Extended spectrum betalactamases (ESBL), AmpC betalactamases and Metallo betalactamases in *Pseudomonas* isolates by phenotypic methods.
4. To correlate the association of risk factors with Chronic suppurative otitis media.

## **REVIEW OF LITERATURE**

### **DEFINITION**

Chronic suppurative otitis media (CSOM) is defined as a chronic inflammation of the middle ear and mastoid cavity, which presents with recurrent ear discharges or otorrhoea through a tympanic perforation.<sup>(1)</sup> Though the WHO definition requires only two weeks of otorrhea<sup>(1)</sup>, otolaryngologists tend to adapt a duration of more than 3 months of active disease.<sup>(2)</sup>

CSOM is classified into two types depending on the site of perforation.

#### **Tubotympanic**

Also called the safe or benign type, involving the anteroinferior part of the middle ear cleft and is associated with central perforation. There is no risk of serious complications.

#### **Atticoantral**

Also called the unsafe or dangerous type, involving the posterosuperior part of the middle ear cleft and is associated with attic or marginal perforation. The disease is associated with bone eroding process such as cholesteotoma or granulations and the risk of complications are high in this type of disease.<sup>(3)</sup>

#### **Anatomy of the Ear**

Anatomically ear is divided into three parts

## 1. External ear


Consists of Pinna ,external auditory canal and the tympanic membrane.

The external auditory canal has two parts ,outer one third cartilaginous and inner two thirds bony.

Tympanic membrane is a greyish white membrane set obliquely which separates the external ear from the middle ear. It consists of two parts

Pars Tensa : forms most part of tympanic membrane. It is peripherally thickened to form a fibrocartilagenous ring called annulus which fits in the tympanic sulcus.

Pars Flaccida :is the superior part of tympanic membrane.



## Parts of the Ear–External, Middle and Internal Ear

## **2. Middle Ear**

Consists of the middle ear cavity with the Eustachian tube, the aditus, the mastoid antrum and the air cells of the mastoid.

The middle ear cavity lies between the tympanic membrane laterally and the promontory formed by the basal turn of the cochlea medially and is divided into i) mesotympanum (lying opposite the pars tensa), ii) epitympanum or the attic (lying above the pars tensa), iii) hypotympanum (lying below the level of pars tensa).

## **3. Inner Ear**

The inner ear or the labyrinth is an important organ for hearing and balance. It comprises the cochlea, vestibule, and semicircular canals. Vestibulocochlear nerves connect the inner ear with the brain.

### **Epidemiology**

The prevalence of CSOM varies between racial and socioeconomic groups. Some of the risk factors identified include history of recurrent acute suppurative otitis media, adverse socioeconomic status, overcrowded and limited access to medical care.<sup>(4)</sup> Worldwide, there are between 65-330 million people affected, of whom 60% presents with significant hearing loss. This burden falls disproportionately on children in developing countries.<sup>(11)</sup>

WHO has categorized prevalence rates of 1-2% as low and 3-6% as high prevalence group.

Country prevalence rates by WHO regional classification has categorized India as high prevalence group. (prevalence rate > 4%).<sup>(1)</sup> Incidence of CSOM in India is 46/1000(rural population)and 16/1000(urban areas)<sup>(23)</sup>. It is one of the most common causes of hearing impairment in India because of its prevalence in poor socio economic class.<sup>(24)</sup>

CSOM produces mild to moderate conductive hearing loss in more than 50% of the cases.<sup>(1)</sup>. This is due to the disruption of ear drum and ossicles which causes conductive hearing loss or from hair cell damage with the bacterial infection which has gone into the middle ear (sensory hearing loss) or both (mixed hearing loss).<sup>(1)</sup>

### **TUBOTYMPANIC TYPE OF CSOM**



### **Tubotympanic Type of CSOM**

In this, the disease is confined to the mucosa of Eustachian tube and anteroinferior part of middle ear. It is called safe or benign type of disease as there is no danger to the life of patient.

## **Predisposing factors**

It is a sequelae of acute suppurative otitis media (ASOM) which has not been treated adequately.

Occasionally, a traumatic perforation may get infected leading to CSOM.

Ascending infections via Eustachian tube, infections from tonsils, adenoids and infected sinuses may be responsible for persistent or recurring otorrhoea.<sup>(3)</sup>

Abnormal Eustachian tube function is a predisposing factor seen in children with cleft palate and Down's syndrome.<sup>(4)</sup> Other factors include allergy, malnutrition, hypogammaglobulinemia, and unhygienic personal habits like bathing and swimming in dirty water.

Viral infection would affect the mucosa of the middle ear making it less resistant to the organisms that are normally present in the middle ear ,allowing bacterial overgrowth.<sup>(2)</sup>

CSOM is often associated with poor mastoid pneumatisation. Though mastoid pneumatisation begins in the latter half of embryonic development, the greater part of this takes place in the first five years of life. Poor mastoid pneumatisation are due to

1. Infection in infancy or early childhood prevents normal cellular development.

2. Infection within a pneumatized cleft provokes sclerosis, with obliteration of the cells.
3. Failure of air-cell development predisposes to infection of the middle ear<sup>(4)</sup>

### **Pathogenesis**

The pathological changes seen in tubotympanic type of CSOM are

1. Perforation of the pars tensa
2. Chronic inflammation of middle ear mucosa:

Hyperemia and glandular hypertrophy causing profuse discharge occurs when the disease is active. It may be normal when disease is quiescent or inactive.

3. Polyp: A polyp is a smooth mass of oedematous and inflamed mucosa which has protruded through a perforation and presents in the external canal. It is usually pale in contrast to pink, fleshy polyp seen in atticotympanic disease.
4. Tympanosclerosis: It is hyalinisation and subsequent calcification of the subepithelial connective tissue seen in the remnants of tympanic membrane, ossicles, tendons, oval and round windows causing conductive hearing loss.

5. Ossicular chain: Fibrosis and adhesions occur as a result of healing process impairing the mobility of ossicular chain. <sup>(3)</sup>

## **CLINICAL FEATURES**

### **Tubotympanic type**

Ear discharge : may be continuous or intermittent and varies in character from serous or mucoid or frankly purulent.

Hearing loss : predominantly conductive type of hearing loss. Factors influencing the degree of conductive deafness include size of the perforation, impairment of the ossicular chain and presence of middle ear pathology such as oedema and granulation tissue.

### **Investigation**

Examination under microscope: provides information regarding the presence of granulations, edges of perforation, tympanosclerosis and adhesions.

Audiometry: gives an assessment of degree of hearing loss and its type which is usually conductive hearing loss.

Culture and sensitivity of ear discharge: to identify the pathogens and to select the appropriate antibiotic topical or systemic

Mastoid X rays usually sclerotic may be pneumatised with no evidence of bone destruction.



## **Complications of Tubotympanic type**

Includes

Otitis externa, erosion of ossicular chain, sensory neural hearing loss, vertigo, tympanosclerosis and adhesions in the middle ear.

## **ATTICOANTRAL TYPE OF CSOM**



### **Atticoantral Type of CSOM**

It is also called unsafe or dangerous type of CSOM, as the disease spreads to bony walls of epitympanum, aditus, antrum and mastoid cells causing serious complications.

### **Predisposing factors**

Cholesteatoma (skin in wrong place) keratinising squamous epithelium replaces the ciliated columnar epithelium of the middle ear cleft.

Middle ear mucosa undergoes metaplasia due to repeated infections and transforms to squamous epithelium.

It may also be caused by localised osteitis in which granulations are seen in the attic region.

### **Pathogenesis**

The pathological changes in atticoantral disease include

- Retraction pocket in the attic due to negative intratympanic pressure
- Granulation tissue with keratin masses or flakes providing ideal medium for the growth of bacteria.
- Ossicular necrosis and Cholesterol granuloma<sup>(3)</sup>

### **Clinical features**

Ear discharge: usually scanty and foul smelling due to bone destruction. blood stained discharge indicates presence of granulation and underlying osteitis.

### **Signs**

Perforation: small attic perforation may be missed due to presence of small amount of crusted discharge.

Retraction pocket: an invagination of tympanic membrane is seen in the attic or posterosuperior part of pars tensa.

Cholesteotoma: pearly white flakes of cholesteotoma can be seen in the retraction pockets.

### **Investigations**

Examination under microscope gives information about the extent of the defect, the presence of squamous epithelium, keratin debris and involvement of the ossicular chain or osteitis.

X ray Mastoids useful in the demonstration of anatomical variation and to detect bony erosion.

Culture and sensitivity of the ear discharge to select proper antibiotics.

Computed Tomography is generally the imaging modality of choice in the assessment of cholesteotoma.

### **Complications of Attico antral type**

They are classified into intracranial and extracranial complications.

Intracranial: Mastoiditis, petrositis, facial paralysis and labyrinthitis.

Extracranial: Extradural and subdural abscess, meningitis, brain abscess, lateral sinus thrombosis and otitic hydrocephalus.

Although incidence of complications is declining, these are still seen in india due to poor socio economic conditions ,lack of education and awareness of health care. WHO studies shows that India and Sub-Saharan Africa (SSA)

account for most deaths and years of life lost and DALYs(disability-adjusted life-years) from otitis media.<sup>(1)</sup>

### **Management of CSOM**

The principal aims of management are the eradication of infection and the closure of the tympanic perforation.

#### **Medical**

Treatment with appropriate antibiotics based on antibiotic susceptibility test is effective in bacteriological cure.

#### **Surgical**

Correction of hearing loss and closure of tympanic membrane perforation requires appropriate surgical procedures.

### **Microbiological Profile of CSOM**

A wide range of organisms, both aerobic and anaerobic may be isolated from cases of CSOM. Although the development if CSOM may follow an initial acute infection, the type of micro-organisms found in chronic discharge differ from those found in acute suppurative otitis media.<sup>(2)</sup> The predominance of Gram negative organisms indicates the source of infection is not the nasopharynx, which does not contain these organisms.<sup>(2)</sup> These organisms are likely to gain access to the middle ear from the external auditory canal through the tympanic membrane defect.<sup>(4)</sup>

## **VARIOUS ISOLATES IN CHRONIC SUPPURATIVE OTITIS MEDIA**

### **Aerobic isolates**

#### **Gram positive Bacteria**

*Staphylococcus aureus*

*Coagulase Negative Staphylococcus aureus*

*Streptococcus pneumoniae*

#### **Gram negative bacteria**

*Pseudomonas aeruginosa,*

*Klebsiella pneumonia,*

*Proteus species,*

*Escherichia coli,*

*Acinetobacter species*

*Morganella morganii*

### **Anaerobic isolates**

*Clostridium species,*

*Peptococcus species,*

*Peptostreptococcus species,*

*Bacteroides species.*

## **Fungal isolates**

*Aspergillus niger*,

*Aspergillus fumigates*,

*Candida species*

Though these bacteria are infrequently found in the external auditory canal, they may cause infection of the middle ear due to trauma, inflammation or humidity and are most likely to gain access to the middle ear from the external auditory canal through the perforation<sup>(4)</sup>. *Pseudomonas aeruginosa* has been particularly responsible for deep seated infections and progressive destruction of the middle ear and mastoid through its toxins and enzymes.

In a study by Rajat Prakash<sup>(6)</sup> the most common organism isolated was *Staphylococcus aureus* followed by *Pseudomonas aeruginosa* whereas in a study by V.K. Poorey, and Arati Iyer, the commonest isolate was *Pseudomonas aeruginosa* followed by *Klebsiella species*<sup>(7)</sup>. Many of the previous studies showed *Pseudomonas* to be the most predominant isolate.<sup>(25,26,27,28,29)</sup>.

## **Microbiological characteristics of *Pseudomonas species***

*Pseudomonas* are ubiquitous microorganisms, found in the environments such as water, soil, plants, humans, animals, sewage and hospitals. In humans they are opportunistic pathogens and have great propensity to grow in a variety of environments with minimal nutritional components.<sup>(16)</sup>

It is resistant to the common antiseptics and disinfectants, such as quaternary ammonium compounds, chloroxylenol and hexachlorophene and may even grow profusely in bottles of antiseptic lotions .

### **Historical Perspective**

Until the first half of twentieth century ,the description were inadequate in terms of phenotypic characterisation. Work performed at the university of California, Berkeley proposed the system of classification of pseudomonas species based on phenotypic characteristics.(Stainer et al.1966). Later this was followed by DNA-DNA hybridisation studies that constituted a group that was not phylogenitically uniform.

A clear demonstration of the phylogenetic heterogeneity was eventually achieved by ribosomal RNA(rRNA)-DNA hybridisation as an analytical criterion(Palleroni et al.1973).<sup>(17)</sup>

### **Classification**

Palleroni separated the pseudomonas into five ribosomal RNA homology groups based on rRNA-DNA homology studies whereas Gilardi separated pseudomonas into seven major groups based on phenotypic characteristics.<sup>(18)</sup>

Phenotypic and Genotypic classification of Pseudomonas is as given below.

## **RNA Group I**

Fluorescent Group : *P.aeruginosa*, *P. Fluorescens*, *P. putida*.

Stutzeri group : *P.stutzeri*, *P.mendocina*, CDC Group Vb-3.

Alkaligenes Group : *P.alcaligenes*, *P.pseudoalcaligenes* ,

*Pseudomonas* species group 1 .

## **RNA Group II**

Pseudomallei Group : *Burkholderia mallei*, *Burkholderia pseudomallei*

*Burkholderia cepacia* complex,

*Burkholderia gladioli*, *Pandoraea* species,

*Ralstonia* species, *Cupriavidus* species.

## **RNA Group III**

Weak Oxidiser Group : *Comamonas acidovorans*, *C. terrigena*, *C. testosteroni*,

*Acidovorax delafieldii*, *A. facilis*, *A. temperans*,

*Lautropia mirabilis*, CDC WO-1.

## **RNA Group IV**

Diminuta Group : *Brevundimonas diminuta*, *B. vesicularis*.

**RNA Group V** : *Stenotrophomonas maltophila*

Yellow-Pigmented Group: *P.luteola*, *P.orizohabitans*,



Sphingomonas.paucimobilis.

**H<sub>2</sub>S-Positive Group:** Shewanella putrefaciens,Shewanella algae.

**Halophilic Group:** Alishewanella fetalis,Halomonas venusta,

CDC halophilic nonfermenter group 1

### **Morphology and Cultural Characteristics**

- *Pseudomonas aeruginosa* are straight gram negative rod measuring 0.5 to 0.8 µm by 1.5 to 3.0 µm ,that are strict aerobes and motile by means of polar flagellum.They utilise glucose and other carbohydrates oxidatively and are cytochrome oxidase positive.
- *P.aeruginosa* grow well on ordinary media ,and produce a characteristic fruity grape like odour.
- On MacConkey agar they grow as non lactose fermenting colonies with green pigmentation or metallic sheen.
- On Blood agar the colonies appear as large colonies with metallic sheen, mucoid, rough,or pigmented and often beta haemolytic.
- The colonies of *Pseudomonas aeruginosa* are usually of two types on most solid media.

- One is large and smooth with flat, edges and elevated centres and the other is smooth, rough and convex. Clinical isolates are generally of large type, while the small type is commonly obtained from natural sources. Variation of the large type to small is observed frequently but the reverse is rare.
- A third type of mucoid colony can be obtained from respiratory and urinary tract secretions. The mucoid morphotype is due to the production of polysaccharide, alginate that surrounds the cell.
- Additional colony types can be observed and Jessen(1965) states that at least five types may be distinguished but the type of colony cannot be correlated with other properties of the strain.<sup>(17)</sup>
- Circular, smooth colonies.

Irregular, contoured colonies

Dry, flat colonies

Mucoid colonies

Rugose colonies

Biochemically they are nonfermenter, oxidase positive which can grow optimally at 37° C and can be distinguished from the others in the group by its ability to grow at 42° C. They exhibit the characteristic pigment production of pyocyanin and pyoverdine.

### Key Characteristics of Fluorescent group

TEST	<i>P.aeruginosa</i>	<i>P.fluorescens</i>	<i>P.putida</i>
Pyoverdin	+	+	+
Pyocyanin	+	–	–
Acetamide	V	–	–
Growth at 42 C	+	–	–
No3 reduction	V(74)	V(19)	–
Gelatin hydrolysis	V(46)	+	–

**+** , **90% or more strains positive**

**-** , **90%or more strains negative**

**V**, **11-89%of strains positive.**

### PIGMENTATION

#### Fluorescent (pyoverdin)Pigment

The Fluorescent group is characterised by production of water soluble pyoverdin pigment that fluoresces white to blue-green under ultraviolet light.

#### Pyocyanin pigment

Though all the three members of fluorescent group produce pyoverdin, *P.aeruginosa* is the only species that produces the distinctive blue pyocyanin pigment.

Other water soluble pigments include pyorubin and pyomelanin which imparts red and brown colour respectively.

Pigment production can be enhanced by using Tech and Flo media which contains special peptones and increased concentration of magnesium and sulphate ions.

Other methods to enhance pigment production is by growing the organisms in gelatin, potato or milk containing media.

### **Virulence factor**

*Pseudomonas aeruginosa* is the most common opportunistic pathogen of all pseudomonas species .It produces several substances that enhance the colonization and infection of host tissue.

### Virulence Factors of *Pseudomonas aeruginosa*

Virulence Factor	Biological activity
Alginate	Capsular polysaccharide helps to adhere to the epithelial surface of lungs and forms biofilms.
Pili	Surface appendages that cause adherence to GM-1 ganglioside receptors of epithelial cell surfaces.
Neuraminidase	Removes sialic acid residues from GM -1 ganglioside receptors, facilitation binding of pili.
Lipopolysaccharide	Produces endotoxin which causes sepsis syndrome.
Exotoxin A	Tissue destruction, inhibition of protein synthesis.
Enterotoxin	Interrupts normal gastrointestinal activity, leading to diarrhoea.
Exoenzyme S	Inhibits protein synthesis.
Phospholipase C	Destroys cytoplasmic membrane, destroys pulmonary surfactant, inactivates opsonins.
Elastase	Cleaves immunoglobulins and complement, disrupts neutrophil activity.
Leukocidin	Inhibits neutrophil and lymphocyte function.
Pyocyanins	Suppress other bacteria and disrupts respiratory ciliary activity, cause oxidative damage to tissues particularly lung.

Of all the extracellular enzymes produced by *P.aeruginosa*, exotoxin A is the most toxic causing inhibition of peptide chain elongation and protein synthesis.<sup>(17)</sup>

### **Resistance to antibiotics**

*P.aeruginosa* is notorious for its resistance to antibiotics with more than 50 resistant genes.

The general resistance is due to combination of factors such as low permeability of the cell wall, genetic capacity to express a wide repertoire of resistance mechanisms, resistance through chromosomal mutations and acquiring resistant gene from other organisms via plasmids, transposons and bacteriophages.

The three major mechanisms by which the organisms resist the action of antimicrobial agents include

1. Restricted uptake and efflux
2. Drug inactivation and
3. Mutational changes in target enzymes.<sup>(13)</sup>

### **Mechanisms of Resistance**

#### **Intrinsic Resistance**

Intrinsic Resistance is mediated through multiple efflux pumps, resulting in expulsion of betalactams, chloramphenicol, fluroquinolones, macrolides , sulphonamides ,tetracycline and trimethoprim.

## **Extrinsic Resistance**

Various antibiotics that overcome the intrinsic resistance include, extended spectrum penicillins (piperacillin, ticarcillin), certain third and fourth generation cephalosporins, (ceftazidime and cefipime), carbapenem (imipenem and meropenem), monobactams (aztreonam), fluoroquinolones (ciprofloxacin and levofloxacin), aminoglycosides (gentamicin, tobramycin, and amikacin) and colistin.

But mutational resistance can develop for these antibiotics.

## **Penetration of antibiotics through cell wall**

The outer membrane of *P. aeruginosa* presents a significant barrier to the penetration of antibiotics, restricting the rate of penetration of small hydrophilic molecules and excluding larger molecules.

Hydrophilic antibiotics such as  $\beta$ -lactams and quinolones can only cross the outer membrane by passing through the aqueous channels provided by porin proteins. These porin proteins are barrel shaped associated as trimers. OprD is a specialized porin which has a specific role in the uptake of positively charged amino acids.

Impermeability Mutations is important in carbapenem resistance due to the loss of OprD porin, a protein that forms a narrow transmembrane channel permeable to carbapenems but not betalactams.

Loss of oprD is frequently associated with resistance to imipenem, which requires this porin to cross the outer membrane. Interestingly, meropenem is not affected by loss of oprD, indicating that the carbapenems

have crossed the outer membrane by different channels.<sup>(13)</sup> Resistance to aminoglycosides and colistin has due to overexpression of an outer membrane protein, oprH, which protects the LPS from binding the antibiotics has been observed in laboratory strains of *P.aeruginosa* but less frequently in clinical isolates.<sup>(30)</sup>

## **Efflux Pumps**

Efflux pumps play an important role in multi drug resistant comprising of three protein components, an energy-dependent pump located in the cytoplasmic membrane, an outer membrane porin and a linker protein which couples the two membrane components together.<sup>(31)</sup>

The different antibiotic efflux systems that have been described in *P. aeruginosa* are mexAB-oprM, mexXY-oprM, mexCD-oprJ and mexEF-oprN.<sup>(32)</sup>

mexAB-oprM is responsible for extrusion of  $\beta$ -lactams, quinolones and a range of disinfectants. mexXY-oprM extrudes aminoglycosides mexEF-oprN extrudes carbapenems and quinolones.

The genes are present in all strains but they are not expressed at high levels. However, increased expression result from mutation of the regulatory genes such as mexR, which controls expression of the mexAB-oprM genes.<sup>(33)</sup>

Mutation or upregulation of mexR repressor gene results in efflux pump overproduction and increase in the minimum inhibitory concentration(MIC) of multiple antibiotics but not imipenem.



## **DRUG INACTIVATION**

Inactivation of aminoglycosides occurs through production of enzymes which transfer acetyl, phosphate or adenylyl groups to amino and hydroxyl substituents on the antibiotics. The modifying enzymes are plasmid mediated, consequently spontaneous mutations in cells during antibiotic treatment does not lead to overexpression of the enzymes, as seen with the chromosomal  $\beta$ -lactamases.

## **CHANGES IN TARGET ENZYMES**

In *P. aeruginosa* changes in target enzymes is most commonly encountered with the quinolones through mutation in the *gyrA* gene encoding the A subunit of the target enzyme, DNA gyrase.<sup>(34)</sup>

## **METHODS TO DETECT ANTIBIOTIC RESISTANCE MECHANISMS**

### **Phenotypic methods**

#### **Extended Spectrum Betalactamase**

Represent betalactamases that hydrolyze extended-spectrum cephalosporins (cefotaxime, ceftriaxone, ceftazidime), monobactams (aztreonam) and are not affected by betalactamase and carbapenemase inhibitors.<sup>(35)</sup>

### **Confirmatory methods**

- Double disk diffusion synergy test<sup>(39)</sup>
- Three dimensional test
- Inhibitor potentiated disc diffusion test<sup>(39)</sup>

- ESBL E-strip method
- ESBL agar medium

### **Amp C betalactamase detection**

Isolates showing reduced susceptibility to ceftiofur were considered as screen positive and selected for detection of Amp C betalactamases.

### **Confirmatory methods**

- Amp C disc test
- Modified three dimensional test<sup>(40)</sup>
- Amp C betalactamase E test<sup>(40)</sup>

### **Carbapenemase detection**

A strain that produces carbapenemases presents at least 21 mm diameter to meropenem, imipenem or ertapenem is considered to be positive for Carbapenemase production.<sup>(36)</sup>

- Confirmatory methods
- Modified Hodge test
- Imipenem- EDTA combined disc test
- Imipenem EDTA double disc synergy test
- MBL E-test
- CARBA NP test

## **MATERIALS AND METHODS**

This cross sectional study was conducted in the Institute of Microbiology, in association with Upgraded institute of Otorhinolaryngology, Madras Medical College ,Rajiv Gandhi Government General Hospital, Chennai.

### **Study period**

The study period is for a period of 1 year from October 2014 to September 2015.

### **Study Population**

100 patients with clinical diagnosis of CSOM attending ENT department of RGGGH who satisfied the inclusion criteria were enrolled for the study.

### **Ethical consideration**

Approval was obtained from the Institutional ethics committee before the commencement of the study. Informed consent was obtained from all the patients who participated in the study.

### **Statistical analysis**

Statistical analysis were carried out using Statistical Package for Social Sciences(SPSS).The proportional data of this cross sectional study were tested using One sample Z-test.

### **Study population**

A total of 100 patients with clinical diagnosis of CSOM from the Upgraded Institute of Otorhinolaryngology ,RGGGH ,Chennai were include in the study.

### **Inclusion criteria**

- Patients with clinical diagnosis of CSOM
- Patients older than 13 years.
- Patients who were not on antibiotic (both systemic and topical) treatment for minimum of 24 hours prior to sample collection.

### **Exclusion criteria**

- Patients less than 13 years.
- Patients with acute otitis media.
- Patients not willing to participate in the study.

### **Sample collection**

The ear discharge was collected using sterile swabs under aseptic precautions with the aid of an aural speculum, prior to the instillation of any topical medication. Using sterile swabs .A minimum of three samples were taken. First swab used for direct Gram stain and KOH mount,Second swab for bacterial culture and the third swab for fungal culture based on the KOH mount.

## **Specimen processing**

- Direct Gram stain :  
Shows possible pathogens present in sample.
- KOH mount:  
Detection of fungal elements.

## **Interpretation of bacterial culture**

The swab on reaching the laboratory was inoculated on the following culture media

- Nutrient agar plate
- Mac Conkey agar plate
- 5% Sheep Blood agar plate

After overnight incubation at 37°C aerobically, the plates were examined for growth and culture characteristics were identified.

The isolates were identified by Grams stain morphology, motility, culture characteristics and biochemical reactions by the standard techniques.

The isolated colonies depending on the Gram reaction were subjected to following biochemical tests for identification.

If Gram negative bacilli was seen ,the colonies were subjected to the following tests and biochemical reactions using standard microbiological techniques.

1. Catalase test
2. Oxidase test

3. Nitrate reduction test
4. Hugh-Leifson's Oxidation Fermentation test
5. Indole test
6. Methyl red test
7. Voges Proskauer test
8. Simmon's Citrate utilization test
9. Christensen's Urease test
10. Mannitol motility
11. Triple sugar iron agar
12. 1% Sugar fermentation tests Glucose,Sucrose,Maltose,Mannitol.
13. Lysine decarboxylase,Ornithine decarboxylase and Arginine dihydrolase test.

Identification of *Pseudomonas species* was based on the following culture characteristics and biochemical reactions.

On Nutrient agar- iridescent colonies with metallic sheen are seen.

On MacConkey agar - forms non-lactose fermenting colonies .

On Blood agar - many strains were hemolytic on blood agar. Some of them were non hemolytic.

Isolates that are GramNegative bacilli,catalase positive,oxidase positive and motile by hanging drop were identified as *Pseudomonas species*.

Isolates were identified as *Pseudomonas aeruginosa* by the following characteristics

1. Gram Negative rod
2. Oxidase Positive
3. Fruity grape –like odour
4. Growth at 42°C :*P.aeruginosa* is distinct from the rest of the clinically relevant fluorescent pseudomonas in its ability to grow at 42°C.
5. Nitrate reduction and gas from nitrate
6. Arginine dihydrolase test :Positive
7. Gelatin Hydrolysis :Positive

*Acinetobacter* speciation was done by the following additional tests

1. Presence of growth at 44°C
2. Presence of  $\beta$  hemolysis
3. 10% OF lactose utilization test
4. Malonate utilization.

Isolates that are Gram Positive cocci were subjected to the following tests and biochemical reactions using standard techniques.

1. Catalase test
2. Coagulase test -Slide and Tube coagulase

3. Modified Oxidase test
4. Urease Test
5. Mannitol fermentation test
6. Phenolphthalein phosphatase test
7. Gelatin Liquifaction test
8. Bacitracin susceptibility test using 0.04U disk.

If the Gram positive cocci in clusters that were catalase positive and coagulase negative it was identified as Coagulase negative Staphylococci and the following additional tests were done for speciation of CONS.

1. Carbohydrate fermentation tests using Lactose, Mannitol, Mannose, Xylose and Trehalose
2. Nitrate reduction test
3. Ornithine decarboxylase test
4. Differential disc diffusion test with Novobiocin (5µg) and Polymyxin 300 units.



## **ANTIBIOTIC SUSEPTIBILITY TESTING**

Isolates were subjected for antibiotic susceptibility testing by employing Kirby-Bauer standard disc diffusion method on Muller- Hinton agar according to CLSI guidelines (M100-S24)

### **Antimicrobial susceptibility testing by Kirby-Bauer Disc diffusion method**

1. With a sterile bacteriological wire loop 3-5 well isolated identical colonies were picked up and inoculated in 5ml of peptone water, incubated at 37°C for 3-5 hrs to attain 0.5 McFarland's turbidity.
2. A sterile cotton swab was dipped into it and pressed firmly against the wall of the test tube to remove excess broth from the swab.
3. Dried surface of Mueller Hinton agar plate was swabbed in three directions 60° each time to ensure an even and complete distribution of the inoculums over the entire plate.
4. Inoculated plate was allowed to dry for 3 to 5 minutes with the lid in place before adding the antibiotic discs.
5. The antimicrobial discs were placed on the surface of the agar using forceps. Not more than 6 discs were placed in the plate.
6. After overnight incubation at 37°C, the diameter of zone of inhibition was measured in mm.

Interpretation of Zone of inhibition diameters were done according to CLSI guidelines.

**ATCC control strains:**

- *Staphylococcus aureus*–ATCC 25923
- *Escherichia coli*-ATCC 25922
- *Pseudomonas aeruginosa*-ATCC 27853
- *Klebsiella pneumoniae* (ESBL)-ATCC 700603

The panel of drugs used for antimicrobial susceptibility test of Gram Positive organisms were as follows

Antibiotic	Disc content	Zone of Inhibition in mm		
		Sensitive	Intermediate	Resistant
Penicillin	10 units	$\geq 29$	-	$\leq 28$
Erythromycin	30 $\mu$ g	$\geq 23$	14-22	$\leq 13$
Ciprofloxacin	5 $\mu$ g	$\geq 21$	16-20	$\leq 15$
Amikacin	30 $\mu$ g	$\geq 17$	15-16	$\leq 14$
Cotrimoxazole	1.25/23.75 $\mu$ g	$\geq 16$	11-15	$\leq 10$
Chloramphenicol	30 $\mu$ g	$\geq 18$	13-17	$\leq 12$

The panel of drugs used for antimicrobial susceptibility test of Gram Negative organisms were as follows

Antibiotic	Disc content	Gram negative bacilli	Diameter of Zone of inhibition in mm.		
			Sensitive	Inter mediate	Resistant
Amikacin	30µg	Enterobacteriaceae &Non-fermenters	≥ 17	15-16	≤ 14
Ciprofloxacin	5 µg	Enterobacteriaceae &Non-fermenters	≥21	18-20	≤17
Gentamicin	10µg	Enterobacteriaceae &Non-fermenters	≥15	13-14	≤12
Cotrimoxazole	1.25/ 23.75µg	Enterobacteriaceae &Non-fermenters	≥16	11-15	≤10
Piperacillin-Tazobactam	100µg /10µg	Enterobacteriaceae &Non-fermenters	≥21	18-20	≤17
Cefotaxime	30µg	Enterobacteriaceae	≥26	23-25	≤22
		Acinetobacter	≥23	15-22	≤14
Ceftazidime	30µg	Enterobacteriaceae	≥21	18-20	≤17
		P.aeruginosa& Acinetobacter sp.	≥18	15-17	≤14
Imipenem	10µg	Enterobacteriaceae	≥23	20-22	≤19
		P.aeruginosa	≥19	16-18	≤15

All the isolates of *Pseudomonas aeruginosa* were screened for ESBL, AmpC and MBL production by the following methods. The screen test positive isolates were subjected to respective confirmatory tests using appropriate antibiotic discs.

#### **Extended spectrum $\beta$ -lactamase(ESBL) detection method.**

*Pseudomonas aeruginosa* showing reduced zone of inhibition around ceftazidime(30 $\mu$ g) with reference to CLSI 2014 AST criteria were considered to be ESBL producers.

Using sterile loop, four or five colonies of similar morphology were picked up, inoculated to 5ml peptone water and incubated at 37°C for 4-6hrs until turbidity matches with McFarland 0.5 turbidity standard ( $1.5 \times 10^8$ cfu/ml). Lawn culture was done on Mueller-Hinton agar plates and Ceftazidime and Ceftazidime-clavulanic acid discs are placed 50mm apart from centre to centre.

#### **Interpretation**

Zone of inhibition was measured around the discs with the help of measuring scale. An increase in 5 mm in zone of inhibition in a disc containing clavulanic acid compared to the drug alone is considered as an ESBL producer.

#### **AmpC $\beta$ lactamases detection methods**

##### **Screening for AmpC $\beta$ -lactamase**

*Pseudomonas* isolates were screened for AmpC  $\beta$ -lactamase by using cefoxitin (30 $\mu$ g). Isolates showing reduced susceptibility to cefoxitin (30 $\mu$ g)

with zone diameter less than 18mm were considered as positive and selected for the detection of AmpC  $\beta$ -lactamases by Amp C disc test.<sup>(37)</sup>

#### **Amp C disc test**

- A lawn culture of ATCC E.coli 25922 was prepared on MHA plate.
- Sterile discs of 6mm size was moistened with sterile saline and inoculated with several colonies of test organism.
- The inoculated disc was then placed beside a ceftiofur disc (almost touching on the inoculated plate. The plates were incubated overnight at 35°C.
- Flattening or indentation of the ceftiofur inhibition zone in the vicinity of the test disc were considered as AmpC positive isolate.
- A negative test had an undistorted zone.

#### **Metallo- $\beta$ -lactamase (MBL) detection method**

##### **Screening method for MBL**

*Pseudomonas* isolates were screened for Metallo- $\beta$ -lactamase production by using imipenem (10 $\mu$ g).

Isolates with zone of inhibition less than 15mm were considered as MBL producers.<sup>(38)</sup>

## **DETECTION OF METHICILLIN RESISTANCE IN STAPHYLOCOCCUS AUREUS**

Isolates of *Staphylococcus aureus* were screened for MRSA by standard disc diffusion using cefoxitin(30µg). Isolates with zone of inhibition less than 21mm were considered as Methicillin resistant *Staphylococcus aureus*.

## **FUNGAL CULTURE**

### **KOH Mount**

Direct microscopic examination of the ear discharge was done in 10% KOH. for the presence of epithelial cells ,pus cells, budding yeast cells ,fungal hyphae and spores.

One large drop of 10% KOH was placed on a clean grease free slide mounted with a small quantity of specimen and is mixed well. A sterile cover slip is placed over the drop and left at room temperature for 10 mts for the digestion of the debris. The mount is examined under low and high power for the presence of epithelial cells ,pus cells, budding yeast cells ,fungal hyphae and spores.

## **INTERPRETATION OF FUNGAL CULTURE**

Based on the KOH mount, the ear discharge was also inoculated onto 2 slopes of Sabourad's dextrose agar of pH 5.6 with antibiotics like gentamicin to inhibit bacterial growth and incubated at 25°C and 37°C for 4-6 weeks. The slopes were examined daily during first week and twice a week for the next three weeks. failure of growth even after six weeks was considered as negative for fungal growth and were discarded.

The significance of fungal culture ,in case of commensal or opportunistic fungi being isolated can be established by the following features.

- Isolation of same fungal isolate from all the culture tubes.
- Direct microscopic confirmation of the fungal elements.
- Repeated isolation of the isolate from multiple specimens.

Tubes showing positive cultures were examined for macroscopic and microscopic appearance of the colonies. Any visible growth on either of the slants were examined for Rate of growth, texture, surface pigmentation, pigmentation on the reverse, presence of diffusible pigment.

**Microscopic examination was done by Lactophenol cotton blue(LPCB) mount**

A drop of LPCB was placed on a grease free slide and a small amount of fungal colony midway between the colony edge and centre was placed on the LPCB drop. The growth was teased so as to have a thin spread out and a coverslip is gently dropped to the edge of the mounting fluid to avoid air bubbles. The mount is examined under the microscope.

Identification is based on the following characteristics

- Nature of hyphae (such as septate or aseptate,hyaline or phaeoid,narrow or wide)
- Conidiogenesis (origin, arrangement)
- Conidia (septate, Pigmented or hyaline, shape and conidial wall)

## **RESULTS**

This cross sectional study was conducted in the Institute of Microbiology, Madras Medical College in association with the Upgraded Institute of Otorhinolaryngology, at the Rajiv Gandhi Government General Hospital, Chennai .

A total of 100 patients with CSOM who satisfied the inclusion criteria were included in the study. Out of 100 patients 93 were culture positive while 7 samples showed no growth.




**TABLE 1: ANALYSIS OF AGE DISTRIBUTION IN CSOM**

<b>Age Distribution Vs Culture Results</b>	<b>Number of Cases</b>	<b>Positive Cases</b>	<b>%</b>	<b>NO Growth</b>	<b>%</b>
11-20 Years	8	5	5.38	3	42.86
21-30 Years	26	24	25.81	2	28.57
31-40 years	24	24	25.81	0	0.00
41-50 Years	16	15	16.13	1	14.29
51-60 Years	16	15	16.13	1	14.29
61-70 Years	9	9	9.68	0	0.00
71-80 Years	1	1	1.08	0	0.00
Total	100	93	100	<b>7</b>	100

Table 1 shows the Age wise distribution of the morphotypes in CSOM. Maximum number of patients were in the second decade of life.

**FIG. 1: ANALYSIS OF AGE DISTRIBUTION IN CSOM**




**TABLE 2: ANALYSIS OF GENDER DISTRIBUTION**

Gender Distribution	Frequency	Percentage
Male	57	57
Female	43	43
Total	100	100
P value One Sample Z-Test		0.321

The gender distribution were studied and was found that Males outnumbered females in the ratio of 1.3 : 1.


**FIG.2: ANALYSIS OF GENDER DISTRIBUTION**



**TABLE : 3 DISTRIBUTION OF RISK FACTORS ASSOCIATED  
WITH CSOM**

Associated Features	Number
URTI	42
Allergy	18
Tonsillitis	15
DNS	43

**FIG. 3: DISTRIBUTION OF RISK FACTORS ASSOCIATED  
WITH CSOM**




**TABLE 4 : DISTRIBUTION OF UNILATERAL AND  
BILATERAL CSOM**

	<b>Number</b>	<b>%</b>
Unilateral CSOM	95	95%
Bilateral CSOM	5	5%

Among the 100 patients included in the study, 95 patients has unilateral ear discharge and 5 had bilateral ear discharge .


**FIG. 4: DISTRIBUTION OF UNILATERAL AND BILATERAL CSOM**



**TABLE 5: DISTRIBUTION ACCORDING TO THE TYPE OF CSOM**

Type of CSOM	Number	%
Tubotympanic CSOM	88	88.00
Atticoantral CSOM	12	12.00
Total	100	100
P value One Sample Z-Test		0.0018

**FIG. 5: DISTRIBUTION ACCORDING TO THE TYPE OF CSOM**



**TABLE 6 : ANALYSIS OF CULTURE RESULTS**

Culture results	Number	Percentage
Positive	93	93%
Negative	7	7%

**FIG. 6: ANALYSIS OF CULTURE RESULTS**



**TABLE 7 : MONOMICROBIAL AND POLYMICROBIAL  
DISTRIBUTION IN CSOM**


<b>Age Vs microbial Isolates</b>	<b>Monomicrobial</b>	<b>%</b>	<b>Polymicrobial</b>	<b>%</b>
11-20 Years	5	5.61%	0	0.00
21-30 Years	23	25.84%	2	28.57%
31-40 years	20	22.47%	4	57.14
41-50 Years	15	16.85%	0	0.00
51-60 Years	3	3.37%	0	0.00
61-70 Years	22	24.71%	1	14.28%
71-80 Years	1	1.12%	0	0.00
Total	89	100%	7	100%

Monomicrobial growth was seen in 89 patients, whereas polymicrobial growth was observed in 7 patients .

**TABLE 8: MICROBIAL PROFILE**

Organism	No.of Isolates	%
<i>Pseudomonas aeruginosa</i>	41	39.81
<i>Klebsiella pneumonia</i>	7	6.80
<i>Escherichia coli</i>	5	4.85
<i>Proteus mirabilis</i>	4	3.88
<i>Acinetobacter baumannii</i>	3	2.91
<i>Staphylococcus aureus</i>	32	31.07
<i>Staphylococcus epidermidis</i>	5	4.85
<i>Aspergillus niger</i>	4	3.88
<i>Aspergillus fumigatus</i>	2	1.94
Total	103	100

**FIG. 7: MICROBIAL PROFILE**






**TABLE 9: DISTRIBUTION OF GRAM NEGATIVE  
BACTERIA IN CSOM**


<b>Gram Negative Bacteria</b>	<b>No.of Isolates</b>	<b>%</b>
<i>Pseudomonas aeruginosa</i>	41	68.33
<i>Klebsiella pneumoniae</i>	7	11.67
<i>Escherichia coli</i>	5	8.33
<i>Proteus mirabilis</i>	4	6.67
<i>Acinetobacter baumannii</i>	3	5.00
<i>Total</i>	60	100

**FIG.8. DISTRIBUTION OF GRAM NEGATIVE ISOLATES IN CSOM**



**TABLE 10: ANALYSIS OF GRAM POSTIVE ISOLATES IN CSOM**

<b>Gram Positive Cocci</b>	<b>No.of Isolates</b>	<b>%</b>
<i>Staphylococcus aureus</i>	<b>32</b>	<b>86.49</b>
<i>Staphylococcus epidermidis</i>	<b>5</b>	<b>13.51</b>
Total	<b>37</b>	<b>100</b>

**FIG.9. ANALYSIS OF GRAM POSITIVE ISOLATES IN CSOM****TABLE :11 LIST OF FUNGI ISOLATED IN CSOM**


<b>Fungal</b>	<b>No.of Isolates</b>	<b>%</b>
<i>Aspergillus niger</i>	4	66.67
<i>Aspergillus fumigatus</i>	2	33.33

Fungal culture was positive in 6 patients, out of which 4 were *A.fumigatus* and 2 were *A.niger*.

**TABLE 12: ISOLATES IN POLYMICROBIAL PROFILE**

Orgainsms	Number of patients
S.aureus + E.coli	2
P.aeruginosa + K.pneumoniae	1
K.pneumonia+S.epidermidis	1
P.aeruginosa +S.aureus	1
S.aureus + A.baumannii	1
P.aeruginosa +A.niger	1
Total	7

**FIG.10. ISOLATES ON POLYMICROBIAL PROFILE**



**TABLE 13: ANTIMICROBIAL SUSCEPTIBILITY OF THE  
BACTERIAL ISOLATES**

<b>Antibiotic Sensitivity(S)</b>	<b>Number</b>	<b>Amikacin</b>	<b>Gentamicin</b>	<b>Ciprofloxacin</b>	<b>Piperacillin &amp; Tazobactam</b>	<b>Ceftazidime</b>	<b>Cotrimoxazole</b>	<b>Cefotaxime</b>	<b>Penicillin</b>	<b>Erythromycin</b>	<b>Imipenem</b>	<b>Chloramphenicol</b>
<i>Pseudomonas aeruginosa</i>	41	32	28	31	40	19	NT	NT	NT	NT	41	NT
<i>Klebsiella pneumoniae</i>	7	6	4	4	7	NT	3	1	NT	NT	NT	NT
<i>Escherichia coli</i>	5	4	4	1	5	NT	2	1	NT	NT	NT	NT
<i>Proteus mirabilis</i>	4	4	4	1	4	NT	1	NT	NT	NT	NT	NT
<i>Acinetobacter baumannii</i>	3	3	3	3	3	1	2	NT	NT	NT	1	NT
<i>Staphylococcus aureus</i>	32	29	NT	25	NT	NT	28	NT	10	20	NT	32
<i>Staphylococcus epidermidis</i>	5	5	0	4	NT	NT	2	NT	2	3	NT	5


**TABLE 14.ANTOBIOTIC RESISTANCE PATTERN OF BACTERIAL  
ISOALATES**

<b>Antibiotic Resistance</b>	<b>Number</b>	<b>Amikacin</b>	<b>Gentamicin</b>	<b>Ciprofloxacin</b>	<b>Piperacillin &amp; Tazobactam</b>	<b>Ceftazidime</b>	<b>Cotrimoxazole</b>	<b>Cefotaxime</b>	<b>Penicillin</b>	<b>Erythromycin</b>	<b>Imipenem</b>	<b>Chloramphenicol</b>
<i>Pseudomonas aeruginosa</i>	41	9	13	10	1	22	NT	NT	NT	NT	0	NT
<i>Klebsiella pneumoniae</i>	7	1	3	3	NT	NT	4	6	NT	NT	NT	NT
<i>Escherichia coli</i>	5	1	1	4	NT	NT	2	4	NT	NT	NT	NT
<i>Proteus mirabilis</i>	4	0	0	3	0	NT	3	4	NT	NT	NT	NT
<i>Acinetobacter baumannii</i>	3	0	0	0	0	2	1	NT	NT	NT	NT	NT
<i>Staphylococcus aureus</i>	32	2	NT	7	NT	NT	3	NT	21	10	NT	0
<i>Staphylococcus epidermidis</i>	5	0	NT	1	NT	NT	3	NT	3	2	NT	0

**TABLE 15 : ANTIBIOTIC PROFILE OF *Pseudomonas aeruginosa***

<b>Pseudomonas aeruginosa N=41</b>	<b>Sensitive</b>	<b>%</b>	<b>Resistant</b>	<b>%</b>	<b>P value One Sample Z-Test</b>
Amikacin	32	78.05	9	21.95	0.0001
Gentamicin	28	68.29	13	31.71	0.0062
Ciprofloxacin	31	75.61	10	24.39	0.0091
Piperacillin & Tazobactam	40	97.56	1	2.44	0.0001
Ceftazidime	19	46.34	22	53.66	0.5713
Imipenem	41	100.00	0	0.00	0.0001


**FIG.11. ANTIBIOTIC PROFILE OF PSEUDOMONAS AERUGINOSA**



**TABLE 16: ANTIBIOTIC PROFILE OF  
STAPHYLOCOCCUS AUREUS**

<b>Staphylococcus aureus N=32</b>	<b>Sensitive</b>	<b>%</b>	<b>Resistant</b>	<b>%</b>	<b>P value One Sample Z-Test</b>
Amikacin	29	90.63	2	6.25	0.0001
Ciprofloxacin	25	78.13	7	21.88	0.0001
Cotrimoxazole	28	87.50	3	9.38	0.0001
Penicillin	10	31.25	21	65.63	0.0062
Erythromycin	20	62.50	10	31.25	0.0051
Chloramphenicol	32	100.00	0	0.00	0.0001


**FIG.12. ANTIBIOTIC PROFILE OF STAPHYLOCOCCUS AUREUS**



**TABLE 17: ANTIMICROBIAL SUSCEPTIBILITY PATTERN OF  
KLEBSIELLA PNEUMONIAE**

<b>Klebsiella pneumonia N=7</b>	<b>Sensitive</b>	<b>%</b>	<b>Resistant</b>	<b>%</b>	<b>P value One Sample Z-Test</b>
Amikacin	6	85.71	1	14.29	0.0001
Gentamicin	4	57.14	3	42.86	0.3210
Ciprofloxacin	4	57.14	3	42.86	0.3210
Piperacillin & Tazobactam	7	100.00	0	0.00	0.0001
Cotrimoxazole	3	42.86	4	57.14	0.3210
Cefotaxime	1	14.29	6	85.71	0.0001

**FIG.13. ANTIMICROBIAL SUSCEPTIBILITY PATTERN OF K.  
PNEUMONIAE**






**TABLE 18: ANTIMICROBIAL SUSCEPTIBILITY**

**PATTERN OF E.COLI**

<b>Escherichia coli N=5</b>	<b>Sensitive</b>	<b>%</b>	<b>Resistant</b>	<b>%</b>
Amikacin	4	80.00	1	20.00
Gentamicin	4	80.00	1	20.00
Ciprofloxacin	1	20.00	4	80.00
Piperacillin & Tazobactam	5	100.00	0	0.00
Cotrimoxazole	2	40.00	2	40.00
Cefotaxime	1	20.00	4	80.00

**FIG 14: ANTIMICROBIAL SUSCEPTIBILITY**


**PATTERN OF E.COLI**



**TABLE :19 ANTIMICROBIAL SUSCEPTIBILITY PATTERN  
OF P.MIRABILIS**

<b>Proteus mirabilis N=4</b>	<b>Sensitive</b>	<b>%</b>	<b>Resistant</b>	<b>%</b>
Amikacin	4	100.00	0	0.00
Gentamicin	4	100.00	0	0.00
Ciprofloxacin	1	25.00	3	75.00
Piperacillin & Tazobactam	4	100.00	0	0.00
Cotrimoxazole	1	25.00	3	75.00
Cefotaxime	0	0.00	4	100.00


**FIG. 15. ANTIMICROBIAL SUSCEPTIBILITY PATTERN  
OF P.MIRABILIS**



**TABLE 20: ANTIMICROBIAL SUSCEPTIBILITY PATTERN  
OF A.BAUMANNII**

<b>Acinetobacter baumanni N=3</b>	<b>Sensitive</b>	<b>%</b>	<b>Resistant</b>	<b>%</b>
Amikacin	3	100.00	0	0.00
Gentamicin	3	100.00	0	0.00
Ciprofloxacin	3	100.00	0	0.00
Piperacillin & Tazobactam	3	100.00	0	0.00
Ceftazidime	1	33.33	2	66.67
Cotrimoxazole	2	66.67	1	33.33

**FIG.16. ANTIMICROBIAL SUSCEPTIBILITY PATTERN  
OF A.BAUMANNII**



**TABLE 21: DETECTION OF ESBL IN PSEUDOMONAS  
AERUGINOSA**

<b>ESBL Production</b>	<b>No of isolates</b>	<b>Percentage</b>
Positive	7	17.07%
Negative	34	82.92%

**TABLE 22: DETECTION OF AMPC BETALACTAMASE IN  
PSEUDOMONAS AERUGINOSA**

<b>AmpC Beta Lactamase</b>	<b>No.of Isolates</b>	<b>Percentage</b>
Positive	4	9.75%
Negative	37	90.24%

**TABLE 23: DETECTION OF MBL IN PSEUDOMONAS  
AERUGINOSA**

<b>Screening Test for MBL</b>	<b>No of Isolates</b>	<b>Percentage</b>
Positive	0	0.00%
Negative	41	100%

## DISCUSSION

Chronic Suppurative Otitis Media(CSOM) is considered as a major public health problem,in the developing world and India is one of the countries with high prevalence where urgent attention is needed.<sup>(1)</sup>

It is a persistent disease with risk of irreversible complications and is an important cause of preventable hearing loss in adults and children.<sup>(41)</sup>

Since chronic suppurative otitis media is a disease which can cause significant morbidity, early microbiological diagnosis ensures effective treatment.<sup>(42)</sup> Hence knowledge of pathogens and their antibiotic susceptibility pattern would guide the treating physicians in selection of appropriate antibiotics which would help us in reducing the complications and emergence of resistant strains.<sup>(43)</sup>

This cross sectional study which was conducted in the Institute of Microbiology in association with the Upgraded Institute of Otorhinolaryngology, Madras Medical College,Chennai, included 100 patients with clinical diagnosis of CSOM.

In the present study ,105 samples (pus from the middle ear) were obtained from 100 patients. Out of 100 patients, five had bilateral ear discharge accounting for 105 samples. Among 100 patients 93 were culture positive for aerobic bacteria and fungi.

Out of the five patients who had bilateral ear discharge- one patient had the same organism infecting both the ears and two had different organisms affecting each ear and two had growth in single ear .

Analysis of Age distribution showed peak incidence of CSOM in the second decade of life. Prakash et al in their study has reported peak incidence in the first decade of life.<sup>(8)</sup>

In the present study majority of patients had tubotympanic type of CSOM (88%) as compared to atticoantral type(12%). Sharma et al in their study has documented 72% of the cases as the safe or tubotympanic type and 28% as atticoantral type.

Monomicrobial growth was seen in 89 patients, whereas 7 showed polymicrobial growth .No growth was observed in 7 samples .

Aslam et al, in their study showed that out of 142 samples studied , 76% of them were pure and 23.9% were mixed cultures.<sup>(44)</sup> Poorey and Iyer from India in their study isolated pure growth from 82, mixed growth from 10 samples out of 100 samples included.<sup>(45)</sup>

Analysis of bacterial profile of the present study showed that Gram negative bacilli outnumbered Gram positive cocci which is similar to studies by Naheed et al <sup>(51)</sup> and Kulchal et al<sup>(52)</sup>. The predominant pathogen was *Pseudomonas aeruginosa* (39.6%) , followed by *Staphylococcus aureus* (31.68%), *Klebsiella pneumoniae*(6.8%), *Escherichia coli*(4.8%), and *Proteus*

mirabilis(3.8%)and *Acinetobacter baumannii*(2.9%). This is in concordance with many previous studies .<sup>(46,47,48,49,50)</sup> Shyamala *et al* have found that *Pseudomonas aeruginosa* and *Staphylococcus* species are the commonest organism isolated from otitis media.<sup>(46)</sup> In contrast, Prakash et al in their study has documented *Staphylococcus aureus* to be the predominant isolate comprising of 48.69% of the total followed by *Pseudomonas aeruginosa*.

These studies depict that the microbial profile vary between different regions,based on patient population and geographical distribution and hence necessitates the need for frequent analysis and update of the microbial profile in every region.

*Pseudomonas aeruginosa*, the predominant cause of CSOM in tropical region usually does not inhabit the upper respiratory tract, its presence in the middle ear cannot be ascribed to an invasion through Eustachian tube and it is considered to gain access to the middle ear via defect in TM.

Prakash et al<sup>(6)</sup> in their study reported Coliforms including *Klebsiella pneumoniae* and *Escherichia coli* in 9.42% and 7.33% cases respectively,and these findings were tandem to the study done by Mansoor et al.<sup>(57)</sup> who reported *K. pneumoniae* in 8% and *E. coli* in 4% whereas Poorey and Iyer<sup>(45)</sup> in their study has reported a high incidence of *Klebsiella* (25.4%).

A recent study by Shyamala and Reddy showed a different trend where *E. coli* was reported in 12% and *Klebsiella* in 5% of cases.<sup>(53)</sup> Frequent isolation of coliforms like *Escherichia coli* and *Klebsiella* indicates that individuals are

at high risk of acquiring infection when they are exposed to water contaminated with faecal flora while bathing or in activities like swimming.

The Gram positive organisms isolated in the present study were *Staphylococcus aureus* (31%) and *S.epidermidis*(4.8%) which is similar to the studies done by Ettehad et al<sup>(68)</sup> and Singh et al<sup>(69)</sup> ,whereas Prakash et al has documented higher rate of isolation of *Staphylococcus aureus*(48.69%) in their study.

In the present study ,fungal culture was done in 25 patients based on the KOH mount and was positive in 6 patients.

Among the six fungal isolates , four were *Aspergillus niger*(66.67%) and two were *Aspergillus fumigates*(33.33%). In a study from Haryana, India, fungal etiology was found in 15% of cases, out of which 60% were *Candida* species and 40% were *Aspergillus* species.<sup>(54)</sup> Sen Gupta et al reported 74.2% of *Aspergillus* species and 19.3% of *candida* species among the fungal isolates.<sup>(55)</sup> In contrast U Mohan et al in their study on 182 samples reported 25 fungal isolates of which 60% were *Candida* species and 40% were *Aspergillus* species.<sup>(56)</sup>

### **Antimicrobial Susceptibility**

In the present study, antibiotic susceptibility testing was done for all the isolated organisms by Kirby-Bauer disc diffusion method as per CLSI guidelines. Antibiotic susceptibility pattern of *P.aeruginosa* revealed 100%



susceptibility to Imipenem, while 97% of the isolates were sensitive to Piperazillin-tazobactam, 78% to Amikacin, 75% to Ciprofloxacin, 68% to Gentamicin and 46% to Ceftazidime. The sensitivity pattern of *Pseudomonas aeruginosa* was similar to the studies done by Gulati et al.,<sup>(58)</sup> and Mishra et al.<sup>(59)</sup> and Lee et al.<sup>(60)</sup> in which the authors have documented 100% susceptibility to Imipenem followed by Piperacillin-Tazobactam, Amikacin and Ciprofloxacin.

Mansoor T et al in their study showed that amikacin was active against 96% of the isolates of *Pseudomonas*, followed by ceftazidime (89%).<sup>(61)</sup>

Aminoglycosides are bactericidal antibiotics that interfere with protein synthesis and are frequently used because of its activity against Gram negative bacteria. In the present study majority of the *Pseudomonas aeruginosa* isolates were found to be more sensitive to amikacin than gentamicin and this finding is similar to previous studies in Sharma et al, Nepal<sup>(62)</sup>, Saini et al, India<sup>(63)</sup> and Wario et al from Nigeria.<sup>(64)</sup>

Fluoroquinolones inhibits the bacterial DNA gyrase or the topoisomerase II thereby inhibiting DNA transcription and replication. They have a broad range of activity and found to be active against *Pseudomonas aeruginosa*. In the present study 75% of *P. aeruginosa* was found to be sensitive to ciprofloxacin which is similar to various studies that has reported 90% Sensitivity to ciprofloxacin.

Ceftazidime is a most frequently prescribed third generation cephalosporin that has an extended Gram negative spectrum. However resistance to ceftazidime is increasing ,complicating the management of patients with such isolates.

In the present study, 53% of isolates of *P.aeruginosa* were resistant to Ceftazidime which is in concordance to the study conducted by Sabiranatah et al<sup>(65)</sup> in which 54% of the *Pseudomonas* isolates showed 54% resistance to ceftazidime. Contrary to this , the study by chavan et al <sup>(66)</sup> has reported 84% sensitivity to ceftazidime.

Ceftazidime resistance is mainly mediated by production of  $\beta$ -lactamases such as ESBL, MBL and occasionally AmpC- $\beta$ -lactamases <sup>(67)</sup> Besides production of various  $\beta$ -lactamases, other mechanisms such as the lack of drug penetration due to mutation in porins, loss of certain outer membrane proteins and efflux pumps may also contribute for resistance to  $\beta$ -lactams.

In the present study the rates of ESBL,Amp C and MBL were determined among the isolates of *Pseudomonas* resistant to ceftazidime.

In the present study out of 41 isolates of *P.aeruginosa*, <sup>(7)</sup> 17.07% were found to be positive for ESBL production. These observations suggest that the ESBLs which are generally widespread among members of Enterobacteriaceae are also increasingly found in *P. aeruginosa*. This is in concordance with the studies of Aggarwal et al and Picao et al who documented ESBL production of about 21% .<sup>(70,71)</sup>

ESBL producing organisms are frequently resistant to other classes of antibiotics, including aminoglycosides and fluoroquinolones due to the coexistence of genes encoding drug resistance to other antibiotics on the plasmids which encode ESBL.

With regard to AmpC  $\beta$ -lactamases in the present study 9.75% of the *P.aeruginosa* isolates were observed to produce AmpC producer but the study done by Parveen et al, AmpC production was observed in 55.5% of the ceftazidime resistant *Pseudomonas* spp<sup>(72)</sup>.

All the isolates of *P.aeruginosa* were sensitive to Imipenem and there were no MBL producers in the present study.

The second most commonly isolated organism in our study was *Staphylococcus aureus* comprising of 32% of the isolates. All the isolate of *staphylococcus aureus* were found to be methicillin sensitive(MSSA) where 90% of the isolates were sensitive to amikacin, 87% to cotrimoxazole, 78% to ciprofloxacin and 62% to Erythromycin. This correlates with the reports of the study done by Prakash et al where out of 181 isolates, 48% of isolates were *Staphylococcus aureus* and all were found to be methicillin sensitive.

In our study *Escherichia coli* showed 80% sensitivity with Amikacin 20% sensitivity to ciprofloxacin. The sensitivity of *Proteus mirabilis* was good with amikacin and gentamicin. *Klebsiella pneumoniae* showed 85% sensitivity with amikacin and 57% sensitivity with both ciprofloxacin, and gentamicin.

CSOM is generally treated by oral medications with quinolone antibiotic drops such as ciprofloxacin. The absence of oral formulations of Ceftazidime, Cefipime and Imipenem has severely limited the use of these antibiotics in patients with CSOM otorrhea, thus restricting the ability of these bacteria to develop resistance to these antibiotics. This may explain, why resistance to Imipenem in bacteria from CSOM otorrhea is lower than in other types of bacterial infection.<sup>(73,74)</sup>

Multidrug resistant in *Pseudomonas aeruginosa* is classified as resistance to more than three antimicrobial categories.<sup>(75)</sup>

In the present study isolation rate of multidrug resistant *Pseudomonas aeruginosa* was found to be 9.75%. Similar results were obtained in the study by Lee et al.<sup>(76)</sup>

The present study has showed that CSOM infections are commonly caused by *Pseudomonas aeruginosa* followed by *Staphylococcus aureus*. However *Pseudomonas* infections are becoming less sensitive against commonly used antimicrobials like ciprofloxacin, cephalosporins, and gentamicin. Resistance to antimicrobial agents is an increasing public health threat. It limits therapeutic options and leads to increased morbidity and mortality. The important factor that is responsible for resistance is inappropriate use of antibiotics. It is essential to follow antibiotic policies which guides judicious and appropriate use antibiotics to prevent emergence and spread of resistant pathogens.

Hence Continuous and periodic evaluation of microbiological pattern and antimicrobial sensitivity of the isolates is necessary to decrease the risk of complications and emergence of resistant microorganisms by early institution of appropriate treatment.

## SUMMARY

- A total of 100 patients with clinical diagnosis of CSOM from the Upgraded Institute of Otorhinolaryngology were included in the study.
- There was a male predominance among the cases(57%)
- Analysis of age distribution showed maximum no of patients with CSOM in the second decade of life.
- The risk factors associated include upper respiratory tract infection,allergy,tonsillitis and deviated nasal septum. Many patients had more than one risk factor associated with CSOM.
- Out of 100 patients ,88 patients had tubotympanic (safe) type of CSOM,and 12 had atticoantral type of CSOM.
- Analysis of culture results showed culture positive in 93 patients and no growth was observed in 7 patients.
- In the present study out of 100 patients ,95 patients had unilateral CSOM and 5 had ear discharge from both the ears.
- Monomicrobial growth was observed in 89 patients and polymicrobial in 7 patients.All the 5 patients who had bilateral CSOM had monomicrobial growth.One patient had the same organism infecting both the ears and two had different organisms affecting each ear and two had growth in single ear.

- Analysis of bacterial flora showed predominance of *Pseudomonas aeruginosa* (39.6%) followed by *Staphylococcus aureus*(31.68%).
- The other Gram negative isolates isolated were *Klebsiella pneumonia*(6.8%), *E.coli*,(4..8%). *P.mirabilis*(3.8%) and *Acinetobacter baumannii*(2.9%).
- The Gram Positive organisms isolated include *Staphylococcus aureus*(31.68%) and *S.epidermidis*(4.8%).
- In the present study fungal culture was done based on the KOH mount and was positive in 6 patients .Among the six fungal isolates,4 were *A.niger* and two were *A.fumigatus*.
- In the present study for all the isolates Amikacin was found to be the most effective drug followed by ciprofloxacin and gentamicin.
- Antimicrobial susceptibility of *Pseudomonas aeruginosa* revealed 100% sensitive to imipenem,97% sensitive to piperazillin-tazobactam,78% to amikacin ,75% to ciprofloxacin , 68% to gentamicin and 46% to ceftazidime.
- ESBL producers in *Pseudomonas aeruginosa* was found to be 17.07%,AmpC betalactamase was found in 9.75%
- There were no MBL producers as all the isolates of *P.aeruginosa* were sensitive to imipenem.
- Multidrug resistant *Pseudomonas aeruginosa* was found in 9.75%

## CONCLUSION

Chronic suppurative otitis media is a major health problem in developing countries causing serious local damage and threatening complications.

In the present study *Pseudomonas aeruginosa* was the major pathogen in the etiology of CSOM followed by *Staphylococcus aureus*. These organisms are found to be less susceptible to the routinely used drugs like ciprofloxacin and cephalosporins. This may be due to important factor that the cultures are mostly requested when commonly used drugs have failed to eradicate the infection. . Hence appropriate antimicrobial drugs should be prescribed after proper diagnosis of the causative organism and its antimicrobial susceptibility pattern.


The results of this study indicates that ESBL and AmpC production is a major mechanism of resistance to cephalosporins among the isolates of *P.aeruginosa*.

The emergence of *P. aeruginosa* possessing combinations of  $\beta$ -lactamases like ESBL and AmpC betalactamases is a major public health concern necessitating efficient detection and intervention to control drug resistance.

Hence continuous and periodic evaluation of microbiological pattern and antibiotic sensitivity is essential to reduce the potential risk of complications and emergence of resistant strains.



**DIRECT GRAM STAIN SHOWING GRAM NEGATIVE BACILLI**



**COLONIES OF PSEUDOMONAS AERUGINOSA  
ON NUTRIENT AGAR PLATE**



**COLONIES OF PSEUDOMONAS AERUGINOSA ON  
BLOOD AGAR PLATE**




**AMPC DISC TEST FOR AMPC BETALACTAMASE DETECTION**



**PHENOTYPIC CONFIRMATORY METHOD FOR ESBL**



**LPCB MOUNT OF ASPERGILLUS FUMIGATUS**



**LPCB MOUNT OF ASPERGILLUS NIGER**



## **APPENDIX –I**

### **ABBREVIATIONS**

CSOM	-	Chronic Suppurative Otitis Media
URTI	-	Upper Respiratory Tract Infection
DNS	-	Deviated Nasal Septum.
CLSI	-	Clinical & Laboratory Standards Institute
ATCC	-	American Type Culture Collections
GNB	-	Gram Negative Bacilli
GPC	-	Gram Positive Bacilli
MH broth	-	Mueller Hinton broth
MHA	-	Mueller Hinton Agar
MIC	-	Minimum Inhibitory Concentration
MRSA	-	Methicillin Resistant Staphylococcus aureus
MSSA	-	Methicillin Sensitive staphylococcus aureus
PCDDT	-	Phenotypic Confirmatory Disk Diffusion Test
DDST	-	Double Disc Synergy Test
ESBL	-	Extended Spectrum Beta Lactamase
MBL	-	Metallo BetaLactamase
MHT	-	Modified Hodge Test
LPCB	-	Lactophenol cotton blue
NT	-	Not tested
AK	-	Amikacin
GM	-	Gentamicin

CIP	-	Ciprofloxacin
PT	-	Piperacillin Tazobactam
CAZ	-	Ceftazidime
COT	-	Cotrimoxazole
CTX	-	Cefotaxime
PEN	-	Penicillin
ERY	-	Erythromycin
CX	-	Cefoxitin
IMP	-	Imipenem
CHLOR	-	Chloramphenicol

## **APPENDIX –II**

### **A. STAINS AND REAGENTS**

#### **I. Gram staining**

Methyl violet (2%)	10g Methyl violet in 100ml absolute alcohol in 1litre of distilled water (primary stain)
Grams Iodine	10g Iodine in 20g KI (fixative)
Acetone	Decolourising agent
Carbol fuchsin 1%	Secondary stain

#### **II. 10% KOH**

Potassium hydroxide	10g
Glycerol	10ml
Distilled water	80ml

#### **III. Lactophenol cotton blue stain:**

Lactic acid	20 ml
Phenol	20ml
Cotton blue (dye)	0.5g
Glycerol	40ml
Distilled water	20ml

### **B. MEDIA USED:**

#### **1. Nutrient agar**

Peptic digest of animal tissue	5g
Sodium chloride	5g

Beef extract	1.5g
Yeast extract	1.5g
Agar	15gm
Final pH	7.4±0.2

Suspend 28 grams in 1000 ml distilled water. Heat to boiling to dissolve the medium completely and sterilized by autoclaving at 15 lbs pressure (120°C) for 15 minutes.

## 2. Mac Conkey agar

Peptone	20g
Sodium taurocholate	5g
Distilled Water	1 ltr
Agar	20g
2% neutral red in 50% ethanol	3.5ml
10% lactose solution	100ml

Dissolve peptone and taurocholate in water by heating. Add agar and dissolve it in steamer. Adjust pH to 7.5. Add lactose and neutral red shake well and mix. Heat in free steam (100°C) for 1 hour, then autoclave at 115°C for 15 minutes.

## 3. Blood agar (5% sheep blood agar)

Peptone	10g
NaCl	5g
Distilled water	1 Ltr
Agar	10g

Dissolve ingredients in distilled water by boiling, and add 5% sheep blood(sterile) at 55°C adjust pH to 7.4.

**4. Sabouraud's dextrose agar**

Dextrose 40g

Peptone 10g

Agar 20g

Distilled water 1000ml

pH = 5.5

Sterilise by autoclaving at 121°C for 20 min

**5. Mueller Hinton Agar:**

<b>Ingredients</b>	<b>Gms / Litre</b>
Beef, infusion	300.000
Casein acid hydrolysate	17.500
Starch	1.500
Agar	17.000

Final pH (at 25°C) 7.3±0.1

Suspend 38 grams in 1000 ml distilled water. Heat to boiling to dissolve the medium completely. Sterilize by autoclaving at 15 lbs pressure (121°C) for 15 minutes.

Cool to 50o C .Add aseptically 5ml of sterile sheep blood to 95 ml of the agar. Mix well and dispense in aseptically into sterile petri dish.

**B. MEDIA REQUIRED FOR BIOCHEMICAL IDENTIFICATION:**

**1. Oxidase Reagent**

Tetra methyl p-phenylene diamine dihydrochloride- 1% aqueous solution.

**2. Catalase**

3% hydrogen peroxide



### 3. Indole test

#### Kovac's reagent

Amyl or isoamyl alcohol	150ml
Para dimethyl amino benzaldehyde	10g
Concentrated hydrochloric acid	50ml

Dissolve the aldehyde in the alcohol and slowly add the acid. Prepare in small quantities and store in the refrigerator. Shake gently before use.

### 4. Christensen's Urease test medium

Peptone	1g
Sodium chloride	5g
Dipotassium hydrogen phosphate	2g
Phenol red	6ml
Agar	20g
Distilled water	1 ltr
10% sterile solution of glucose	10ml
Sterile 20% urea solution	100ml

Sterilize the glucose and urea solutions by filtration. Prepare the basal medium without glucose and urea, adjust to pH 6.8-6.9 and sterilize by autoclaving in a flask at 121°C for 30min. Cool to about 50°C, add the glucose & urea, and tube the medium as slopes.

### 5. Simmon's Citrate Medium

Koser's medium	1 ltr
Agar	20g
Bromothymol blue	0.2% 40ml

Dispense, autoclave at 121°C for 15 min and allow to set as slopes

**6. Triple Sugar Iron medium**

Beef extract	3g
Yeast extract	3g
Peptone	20g
Glucose	1g
Lactose	10g
Sucrose	10g
Ferric citrate	0.3g
Sodium chloride	5g
Sodium thiosulphate	0.3g
Agar	12g
Phenol red 0.2% solution	12ml
Distilled water	1 ltr

Heat to dissolve the solids, add the indicator solution, mix and tube.

Sterilize at 121°C for 15 min and cool to form slopes with deep butts.

**7. Glucose phosphate broth**

Peptone	5g
Dipotassium hydrogen phosphate	5g
Water	1 ltr
Glucose 10% solution	50ml

Dissolve the peptone and phosphate and adjust the pH to 7.6. Filter dispense in 5ml amounts and sterilize at 121°C for 15min. Sterilize the glucose solution by filtration and add 0.25ml to each tube

**Methyl Red Reagent**

Methyl Red	10mg
Ethyl alcohol	30ml
Distilled water	20ml

**Voges Proskauer Reagent****Reagent A:**

Alpha naphthol	5g
Ethyl alcohol	100ml

**Reagent B:**

Potassium hydroxide	40g
Distilled water	100ml

**8. Peptone water fermentation test medium.**

To the basal medium of peptone water, add sterilised sugars of 1% indicator :bromothymol blue with Durham's tube.

Basal medium peptone water

Sugar solutions:

Sugar	1ml
Dislilled water	100ml

pH = 7.6.

**9. Mannitol motility medium**

Agar	5g
Peptone	1g
Potassium nitrate	1g
Mannitol	2g

Phenol red indicator

Distilled water                      1000ml

pH 7.2

**11. Potassium nitrate broth**

Potassium nitrate (KN03)                      0.2gm

Peptone    5.0gm

Distilled water                                      100ml

The above ingredients were mixed and transferred into tubes in 5 ml amount and autoclave.

**12. 2% Sodium deoxycholate solution:**

**Ingredients :**

Sodium deoxycholate                              2 gms

Distilled water                                      100ml

Dissolve 2 gms of deoxycholate in 100 ml of distilled water .Mix well.Store in a sterile containers.

**8. Decarboxylase media:**

**8a. Moller decarboxylase broth base:**

<b>Ingredients</b>	<b>gms/L</b>
Peptone	5
Beef extract	5
Bromocresol purple	0.01
Cresol red	0.005
Glucose	0.5
Pyridoxal	0.005

Final pH 6

**8b. Aminoacid:**

Add 10 g of the levo form of the aminoacid for 1000ml.mix and dispense in sterile tubes.

**9. Hugh & Leifson's Oxidation –Fermentation test:**

Peptone	2g
Sodium chloride	5g
D-glucose	10g
Bromothymol blue	0.03g
Agar	3.0g
Dipotassium phosphate	0.30g
Distilled water	1L
pH =7.1	

Basal medium is autoclaved.1% of sterile sugar solutions is added to the basal medium.Dispense into sterile test tubes without slant.

## ANNEXURE -I

### **INSTITUTIONAL ETHICS COMMITTEE** **MADRAS MEDICAL COLLEGE, CHENNAI-3**

EC Reg No.ECR/270/Inst./TN/2013

Telephone No. 044 25305301

Fax : 044 25363970

### **CERTIFICATE OF APPROVAL**

To

Dr. Sangeetha Baskaran,  
Postgraduate M.D.(Microbiology),  
Madras Medical College,  
Chennai - 600 003.

Dear Dr.Sangeetha Baskaran,

The Institutional Ethics Committee has considered your request and approved your study titled "**Evaluation of bacterial and fungal etiological agents of chronic suppurative otitis media with special reference to antimicrobial resistance pattern of pseudomonas species**". No.19102014.

The following members of Ethics Committee were present in the meeting held on 07.10.2014 conducted at Madras Medical College, Chennai-3.

- |   |                      |
|---|----------------------|
| 1. Dr.C.Rajendran, M.D.,  | : Chairperson        |
| 2. Dr.R.Vimala, M.D., Dean, MMC, Ch-3   | : Deputy Chairperson |
| 3. Prof.B.Kalaiselvi, M.D., Vice-Principal, MMC, Ch-3                           | : Member Secretary   |
| 4. Prof.R.Nandhini, M.D., Inst.of Pharmacology, MMC                             | : Member             |
| 5. Prof.K.Ramadevi, Director i/c, Inst.of Biochemistry, MMC                     | : Member             |
| 6. Prof.Saraswathy, M.D., Director, Pathology, MMC, Ch-3                        | : Member             |
| 7. Prof.S.G.Sivachidambaram, M.D., Director i/c, Inst.of Internal Medicine, MMC | : Member             |
| 8. Thiru S.Rameshkumar, Administrative Officer                                  | : Lay Person         |
| 9. Thiru S.Govindasamy, B.A., B.L.,   | : Lawyer             |
| 10.Tmt.Arnold Saulina, M.A., MSW.,  | : Social Scientist   |

We approve the proposal to be conducted in its presented form.

The Institutional Ethics Committee expects to be informed about the progress of the study and SAE occurring in the course of the study, any changes in the protocol and patients information/informed consent and asks to be provided a copy of the final report.

Member Secretary, Ethics Committee

**MEMBER SECRETARY**  
**INSTITUTIONAL ETHICS COMMITTEE**  
**MADRAS MEDICAL COLLEGE**  
CHENNAI - 600 003

## **ANNEXURE –II**

### **PROFORMA**

Name :

Age:

Sex:

Occupation:

Address:

Presenting complaints:

- ☐ Ear discharge R/L/Both
- ☐ Difficulty in Hearing
- ☐ Ear Pain
- ☐ Ringing of ear
- ☐ Fever
- ☐ Vomiting
- ☐ headaches

History of presenting illness:

Past history:

Personal history:

Habits

Treatment History:

General physical examination:

Local examination:

Systemic examination:

Provisional diagnosis:

Investigations

X ray

Mastoids

Lateral View of the Face

Paranasal Sinus

CT scan findings:

Microbiological Investigations:

Direct examination:

Gram stain-

KOH mount-

Bacterial Culture:

- NA
- MAC
- BAP

Fungal culture:

- SDA

Isolate identified in sample:

Antibacterial susceptibility pattern:



## **ANNEXURE –III**

### **CONSENT FORM**

#### **STUDY TITLE**

**Evaluation of bacterial and fungal agents in the aetiology of chronic suppurative otitis media with special reference to antimicrobial resistance pattern of Pseudomonas species”**

I....., hereby give consent to participate in the study conducted by Dr.SangeethaBaskaran, Post graduate at Institute of Microbiology, Madras Medical College, Chennai and to use my personal clinical data and the result of investigations for the purpose of analysis and to study the nature of the disease.

I have read and understood this consent form and the information provided to me.

I have had the consent document explained to me.

I have been explained about the nature of the study.

I have been explained about my rights and responsibilities by the investigator.

I have been informed the investigator of all the treatments I am taking or have taken in the past.

I have not participated in any research study within the past \_\_\_\_\_ month(s).

I am aware of the fact that I can opt out of the study at any time without having to give my reason and this will not affect my future treatment in this hospital.

I am also aware that the investigator may terminate my participation in the study at any time, for any reason, without any consent.

I hereby give permission to the investigators to release the information obtained from me as result of participation in this study to the sponsors, regulatory authorities, Govt. agencies, and IEC. I understand that they are publicly presented.

1. I have understand that my identity will be kept confidential if my data are publicly presented.
2. I have had my questions answered to my satisfaction.
3. I have decided to be in the research study.

I am aware that if I have any question during this study, I should contact the investigator. By signing this consent form I attest that the information given in this document has been clearly explained to me and understood by me, I will be given a copy of this consent document.

I also give consent to give my clinical sample(Pus) for further investigations. I also learn that there is no additional risk in this study.

Name and signature / thumb impression of the participant

Name \_\_\_\_\_

Signature\_\_\_\_\_

Date\_\_\_\_\_

Name and Signature of the investigator

Name \_\_\_\_\_

Signature\_\_\_\_\_

Date\_\_\_\_\_

## ANNEXURE –IV

### Master CHART

S NO	AGE	SEX	EAR- R/L/B	ASSOCIATED FEATURES			DNS	Type of CSOM	Species Identified	ANTIBIOTIC SUSCEPTIBILITY TESTING												
				URTI	ALLERGY	TONSILLITIS				AK	GM	CIP	PT	CAZ	COT	CTX	PEN	ERY	IMP	CHL OR	RESIS TANT PATT ERN	
1	57	F	R	+	–	–	–	AT	P.aeruginosa	S	S	S	S	S	–	–	–	–	S	–		
2	26	F	L	–	–	–	+	TT	P.aeruginosa	R	R	R	S	S	–	–	–	–	S	–		
3	22	M	B-R	+	–	+	–	AT	P.aeruginosa	S	S	S	S	R	–	–	–	–	S	–		
			B-L						S.aureus	S	–	S	–	–	S	–	R	S	–	S		
4	55	M	L	–	–	–	–	TT	P.aeruginosa	S	S	S	S	R	–	–	–	–	S	–		
5	18	F	R	–	+	–	–	TT	K.pneumonia	S	R	S	S	–	R	R	–	–	–	–	ESBL	
6	25	F	L	+	–	–	+	TT	NG													
7	56	M	R	–	–	–	+	TT	S.aureus	S	–	S	–	–	–	–	R	R	–	S		
8	38	F	L	+	–	–	+	TT	P.aeruginosa	R	R	R	S	R	–	–	–	–	S	–	AmpC	
9	21	F	R	–	–	–	+	TT	S.aureus	S	–	R	–	–	S	–	S	R	–	S		
10	45	F	R	+	–	–	+	AT	P.aeruginosa	S	S	R	S	S	–	–	–	–	S	–		
11	57	F	B-R	–	–	–	+	TT	K.pneumonia	S	R	R	S	–	R	R	–	–	–	–	ESBL	
			B-L						NG													
12	78	M	R	+	–	–	–	TT	S.aureus	S	–	S	–	–	S	–	R	R	–	S		
13	45	F	R	–	–	+	+	TT	S.aureus	S	–	S	–	–	S	–	R	R	–	S		
14	21	M	R	+	+	–	–	TT	E.coli	S	S	S	S	–	R	R	–		–	–	ESBL	
									S.aureus	S	–	S	–	–	S	–	R	S	–	S		
15	52	F	R	–	–	–	+	TT	NG													
16	40	F	R	+	–	–	–	TT	P.aeruginosa	S	R	S	S	R	–	–	–	–	S	–	AmpC	

S NO	AGE	SEX	EAR- R/L/B	ASSOCIATED FEATURES				Type of CSOM	Species Identified	ANTIBIOTIC SUSCEPTIBILITY TESTING											
				URTI	ALLERGY	TONSILLITIS				DNS		AK	GM	CIP	PT	CAZ	COT	CTX	PEN	ERY	
17	31	F	R	+	+	—	—	TT	P.aeruginosa	S	R	S	S	R	—	—	—	—	S	—	AmpC
									K.pneumonia	S	S	R	S	—	R	R	—	—	—	—	ESBL
18	60	M	B-R	+	—	—	+	TT	S.aureus	S	—	S	—	—	S	—	R	S	—	S	
			B-L						A.baumannii	S	S	S	S	S	S	—	—	—	—	—	
19	32	M	R	—	—	—	—	TT	P.aeruginosa	R	R	S	S	R	—	—	—	—	S	—	
20	39	F	L					TT	CONS	S	—	S	—	—	S	—	R	R	—	S	
									K.pneumonia	S	S	S	S	—	S	R	—	—	—	—	ESBL
21	25	M	L	—	+	—	—	AT	P.aeruginosa	S	S	S	S	R	—	—	—	—	S	—	
									A.niger												
22	30	M	B-R	—	—	—	—	TT	S.aureus	S	-	R	—	—	S	—	R	S	—	S	
			L						NG												
23	49	M	R	+	—	—	—	TT	K.pneumonia	R	R	R	S	—	R	R	—	—	—	—	ESBL
24	23	M	L	—	—	—	+	TT	S.aureus	S	—	S	—	—	S	—	R	S	—	S	
25	29	F	L	—	—	—	—	TT	S.aureus	S	—	S	—	—	R	—	R	R	—	S	
26	52	F	L	—	—	—	—	TT	A.niger												
27	41	M	L	+	—	—	—	TT	NG												
28	32	M	R	—	+	—	+	TT	S.aureus	S	—	S	—	—	S	—	S	S	—	S	
									P.aeruginosa	S	S	S	S	S	—	—	—	—	S	—	
29	39	M	R	—	—	—	+	TT	S.aureus	S	—	S	—	—	S	—	S	S	—	S	
30	48	F	B-R	+	—	—	—	AT	P.aeruginosa	S	S	S	S	S	—	—	—	—	S	—	
			B-L						P.aeruginosa	S	S	S	S	S	—	—	—	—	S	—	
31	21	M	R	+	—	+	—	TT	P.aeruginosa	S	S	S	S	S	—	—	—	—	S	—	

S NO	AGE	SEX	EAR- R/L/B	ASSOCIATED FEATURES				Type of CSOM	Species Identified	ANTIBIOTIC SUSCEPTIBILITY TESTING											
				URTI	ALLERGY	TONSILLITIS				DNS		AK	GM	CIP	PT	CAZ	COT	CTX	PEN	ERY	
32	26	M	R	–	–	–	+	TT	A.fumigatus												
33	20	M	L	–	–	+	–	TT	S.aureus	S	–	R	–	–	S	–	R	R	–	S	
34	65	M	R	–	–	–	+	TT	A.niger												
35	39	M	R	–	–	+	–	AT	P.aeruginosa	S	S	S	S	S				S	–		
36	23	F	R	+	–	–	–	AT	P.aeruginosa	R	R	S	S	R	–	–	–	–	S	–	ESBL
37	23	F	R	–	–	–	+	TT	S.aureus	R		R	–	–	S	–	S	S	–	S	
38	13	M	R	+	–	+	–	TT	NG												
39	38	F	R	–	–	–	–	TT	P.aeruginosa	S	S	S	S	R	–	–	–	–	S	–	
40	25	F	L	+	–	–	–	TT	P.aeruginosa	S	S	S	S	S	–	–	–	–	S	–	
41	27	F	L	–	–	–	+	TT	P.aeruginosa	S	S	S	S	S	–	–	–	–	S	–	
42	48	F	R	+	–	–	+	TT	P.aeruginosa	R	R	S	S	R	–	–	–	–	S	–	ESBL
43	20	M	L	–	+	–	–	TT	P.aeruginosa	S	S	S	S	R	–	–	–	–	S	–	
44	30	F	L	–	+	–	+	AT	P.aeruginosa	S	S	S	S	S	–	–	–	–	S	–	
45	35	F	R	–	–	–	–	TT	P.aeruginosa	R	R	S	S	R	–	–	–	–	S	–	ESBL
46	14	M	R	–	+	–	+	TT	E.coli	S	S	R	S	–	–	R	–	–	–	–	ESBL
47	34	F	L	–	–	–	–	TT	P.aeruginosa	R	R	S	S	S	–	–	–	–	S	–	
48	58	M	L	–	–	–	+	AT	P.aeruginosa	S	S	S	S	R	–	–	–	–	S	–	
49	63	M	L	+	–	–	–	TT	P.aeruginosa	S	R	S	S	R	–	–	–	–	S	–	
50	35	F	L	–	+	–	–	TT	S.aureus	S	–	S	–	–	S	–	R	S	–	S	
51	15	F	L	+	–	+	+	TT	NG												
52	21	F	L	–	+	+	–	TT	P.aeruginosa	S	S	R	S	R	–	–	–	–	S	–	
53	50	M	L	–	–	–	–	TT	P.aeruginosa	S	S	S	S	R	–	–	–	–	S	–	

S NO	AGE	SEX	EAR- R/L/B	ASSOCIATED FEATURES				Type of CSOM	Species Identified	ANTIBIOTIC SUSCEPTIBILITY TESTING											
				URTI	ALLERGY	TONSILLITIS				DNS		AK	GM	CIP	PT	CAZ	COT	CTX	PEN	ERY	
54	64	F	R	+	–	–	–	AT	P.aeruginosa	S	S	S	S	S	–	–	–	–	S	–	
55	23	M	R	+	–	+	+	TT	CONS	S	–	S	–	–	S	–	R	S	–	S	
56	22	M	R	–	–	–	+	TT	P.aeruginosa	R	R	R	S	S	–				S	–	
57	60	M	R	+	–	–	+	TT	S.aureus	–	–	S	–	–	S	–	R	R	–	S	
58	34	F	L	–	–	–	–	TT	S.aureus	S	–	R	–	–	S	–	R	–	–	S	
									E.coli	S	S	R	S	–	S	R	–	–	–	–	ESBL
59	37	M	L	–	–	–	–	AT	P.aeruginosa	R	R	R	S	R	–	–	–	–	S	–	
60	37	M	R	+	–	–	–	TT	E.coli	S	S	R	S	–	S	S	–	–	–	–	
61	35	M	L	–	–	–	+	TT	Proteus mirabilis	S	S	S	S	–	R	R	–	–	–	–	ESBL
62	55	F	L	–	–	–	–	TT	S.aureus	S	–	S	–	–	S	–	R	S	–	S	
63	22	M	R	+	+	–	+	TT	S.aureus	S	–	S	–	–	S	–	S	S	–	S	
64	68	M	R	+	–	–	–	TT	CONS	S	–	S	–	–	R	–	S	S	–	S	
65	40	M	R	–	–	–	–	TT	E.coli	R	R	R	S	–	R	S	–	–	–	–	
66	36	M	L	–	+	–	–	TT	S.aureus	S	–	R	–	–	R	–	R	R	–	S	
67	35	M	R	+	–	+	+	TT	P.aeruginosa	S	S	R	S	R	–	–	–	–	S	–	ESBL
68	67	M	R	+	–	–	–	TT	S.aureus	S	–	S	–	–	S	–	S	S	–	S	
69	38	M	L	+	+	–	–	TT	Proteus mirabilis	S	S	R	S	–	R	R	–	–	–	–	
70	47	F	R	–	–	–	–	TT	P.aeruginosa	S	S	S	S	S	–	–	–	–	S		
71	46	M	R	–	–	–	+	TT	S.aureus	S	–	S	–	–	S	–	S	S	–	S	
72	56	F	R	+	–	–	–	TT	P.aeruginosa	S	S	S	S	S	–	–	–	–	S	–	
73	27	M	R	–	+	+	+	TT	S.aureus	S	–	S	–	–	S	–	R	S	–	S	

S NO	AGE	SEX	EAR- R/L/B	ASSOCIATED FEATURES				Type of CSOM	Species Identified	ANTIBIOTIC SUSCEPTIBILITY TESTING											
				URTI	ALLERGY	TONSILLITIS				DNS		AK	GM	CIP	PT	CAZ	COT	CTX	PEN	ERY	
74	49	M	R	+	–	–	–	TT	S.aureus	S	–	S	–	–	S	–	R	S	–	S	
75	67	M	R	–	–	–	+	TT	S.aureus	S	–	S	–	–	S	–	R	R	–	S	
76	60	M	R	+	–	–	–	TT	S.aureus	R	–	R	–	–	R	–	R	R	–	S	
77	55	M	L	+	–	+	–	TT	CONS	S	–	R	–	–	R	–	R	R	–	S	
78	34	F	L	–	–	–	–	TT	A.niger												
79	55	F	R	–	–	–	+	TT	S.aureus	S	–	S	–	–	S	–	R	S	–	S	
80	22	M	L	+	+	–	+	TT	S.aureus	S	–	S	–	–	S	–	S	S	–	S	
81	56	M	L	–	–	–	–	TT	P.aeruginosa	S	S	S	S	S	–	–	–	–	S	–	
82	25	M	L	–	–	–	+	TT	S.aureus	S	–	S	–	–	S	–	S	S	–	S	
83	19	M	L	–	+	–	–	TT	NG												
84	45	F	L	–	–	–	–	TT	A.baumannii	S	S	S	S	R	R	–	–	–	–	–	
85	50	M	L	–	–	–	–	TT	Proteus mirabilis	S	S	R	S	–	R	R	–	–	–	–	ESBL
86	45	F	R	+	–	–	–	TT	K.pneumonia	S	S	S	S		S	R	–	–	–	–	ESBL
87	30	F	L	+	–	–	–	TT	K.pneumonia	S	S	S	S		S	S	–	–	–	–	
88	50	F	R	–	–	–	–	TT	P.mirabilis	S	S	R	S		S	R	–	–	–	–	ESBL
89	25	M	R	+	+	–	+	TT	NG												
90	63	M	L	+	–	–	–	TT	A.baumannii	S	S	S	S	R	S	–	–	–	S	–	
									CONS	S	–	S	–	–	R	–	S	S	–	S	
91	46	M	R	–	–	+	+	TT	P.aeruginosa	S	S	S	S	S	–	–	–	–	S	–	
92	28	F	R	+	+	+	+	TT	P.aeruginosa	S	S	S	S	S	–	–	–	–	S	–	
93	37	F	L	–	–	–	+	AT	P.aeruginosa	S	S	R	S	R	–	–	–	–	S	–	
94	65	M	R	–	–	–	–	TT	P.aeruginosa	S	S	S	R	R	–	–	–	–	S	–	

S NO	AGE	SEX	EAR- R/L/B	ASSOCIATED FEATURES				Type of CSOM	Species Identified	ANTIBIOTIC SUSCEPTIBILITY TESTING												
				URTI	ALLERGY	TONSILLITIS				DNS		AK	GM	CIP	PT	CAZ	COT	CTX	PEN	ERY	IMP	
95	55	F	R	+	–	–	+	TT	A.fumigatus													
96	36	M	R	–	–	–	+	TT	S.aureus	S	–	S	–	–	S	–	S	S	–	S		
97	45	F	R	+	–	–	+	TT	P.aeruginosa	S	R	R	S	R	–	–	–	–	S	–	ESBL	
98	13	M	L	–	–	+	+	TT	S.aureus	S	–	S	–	–	S	–	–	–	–	S		
99	35	M	R	–	–	–	–	TT	S.aureus	S	–	S	–	–	S	–	R	S	–	S		
100	70	M	R	+	–	–	+	TT	P.aeruginosa	S	S	R	S	R	–	–	–	–	S	–	AmpC	

AK AMIKACIN

GM GENTAMICIN

CIP CIPROFLOXACIN

PT PIPERACILLIN

TAZOBACTUM

CAZ CEFTAZIDIME

COT COTRIMOXAZOLE

CTX CEFOTAXIME

PEN PENICILLIN

ERY ERYTHROMYCIN

CX CEFOXITIN

IMP IMIPENEM

CHLOR CHLORAMPHENICOL



## BIBLIOGRAPHY

1. Jose Acuin, Philippines.Chronic Suppurative Otitis Media Burden of Illness and Management Options.Switzerland:World Health Organization; 2004
2. Brown W.G.Scott,Scott-Brown's Otolaryngology.6<sup>th</sup> edition. Oxford:Reed Educational and Professional Publishing Ltd; 1997.
3. Dhingra P.L,Diseases of Ear,Nose and Throat.3<sup>rd</sup> edition.New Delhi:Redd Elsevier India Private Limited;2004.
4. Harold Ludman, Tony Wright. Diseases of the Ear.6<sup>th</sup> edition. Great Britain: Oxford University Press ;1998.
5. Ramalingam K.K,Sreeramamoorthy.B,RaviRamalingam,A Short Practice of Otolaryngology.2<sup>nd</sup> edition.Chennai:All India Publishers and Distributers;1997.
6. Rajat Prakash, Deepak Juyal, Vikrant Negi, Shekhar Pal, Shamanth Adekhandi, Munesh Sharma,Microbiology of Chronic Suppurative Otitis Media in a Tertiary Care Setup of Uttarakhand State, India North American Journal of Medical Sciences. 2013 Apr; 5(4)282
7. V. K. Poorey , Arati Iyer Study Of Bacterial Flora In Csom And Its Clinical Significance, Indian Journal of Otolaryngology and Head and Neck Surgery Vol. 54 No. 2, April - June 2002.
8. Prakash M1, Lakshmi K2\*, Anuradha S1, Swathi Gn1 .Bacteriological Profile And Their Antibiotic Susceptibility Pattern Of Cases Of Chronic Suppurative Otitis Media .Asian Jclin Res, Vol 6, Suppl 3, 2013, 210-212.
9. Indudharan R, Haq JA, Aiyar S. Antibiotics in chronic suppurative otitis media: a bacteriologic study. Ann Otol Rhinol Laryngol 1999;108:440-5.

10. Ahmed A, Usman J, Hashim R. Isolates from chronic suppurative otitis media and their antimicrobial sensitivity. Pak Armed Forces Med J 1999;49:82-5.
11. ENT World- Diseases Of The Ear, Nose and Throat (Internet 2010). Available from : <http://www.entworld.co.nr/>.
12. Jensen RG, Homoe P, Andersson M, et al; Long-term follow-up of chronic suppurative otitis media in a high-risk children cohort. Int J Pediatr Otorhinolaryngol. 2011 Jul;75(7):948-54
13. P A Lambert. Mechanisms of antibiotic resistance in Pseudomonas Aeruginosa. Journal of the Royal Society of medicine –supplement no.4,volume 95,2002.
14. Tuli B.S.Textbook of Ear,Nose and Throat.Second edition.New Delhi:Jaypee Brothers Medical Publishers (P) Ltd;2013
15. JangCH,Park SY, Emergence of ciprofloxacin –resistant pseudomonas in chronic suppurative otitis media. Clinical otolaryngology 2002;29:321-3.
16. Gerald L.Mandell,John E.Bennett,Raphael Dolin .Mandell,Douglas and Bennett's Principles and Practice of Infectious Diseases.7<sup>th</sup> edition. Philadelphia,PA:Churchill Living stone Elsevier;2010.
17. S.PeterBorriello,Patrick.R.Murray,GuidoFunke.Topley&Wilson's.Bacteriology.10<sup>th</sup> edition.Salisbury,U K :John Wiley &Sons Ltd;2005; 2009.
18. Washington C.Winn,Stephen D Allen,William M.Janda, Elmer W .koneman .Koneman's Color Atlas and Textbook of Diagnostic Microbiology.6<sup>th</sup> edition.Philadelphia,PA:Lippincott Williams and Wilkins;2006.

19. James Versalovic, Karen C. Carroll, Guido Funke, James H. Jorgensen .  
Manual of Clinical Microbiology. 10<sup>th</sup> edition. Washington  
, DC, USA: ASM Press ; 2011.
20. Sanjana RK, Singh YI, Reddy NS. Aerobic bacteriology of chronic  
suppurative otitis media in a tertiary care hospital: A Retrospective  
study. Journal of college of medical sciences-Nepal 2011;7(2):1-8.
21. Smith AW, Hatcher J, Mackenzie, IJ, Thompson S, Bal J, Mac P,  
Okoth- Olende C, Oburra H, Wanjohi Z. Randomised control of chronic  
suppurative otitis media in Kenyan schoolchildren. Lancet
22. Goycoolea MV, Hueb MM, Ruah C. Definitions and terminology.  
Otolaryngol Clin North America
23. Karan Sharma , Mridu Manjari , Neha Salaria. Middle Ear Cleft in  
Chronic Otitis Media: A Clinicohistopathological Study. Indian J  
Otolaryngol Head Neck Surg December 2013 65 Suppl 3.
24. S H C, M M K, Handi P, Khavasi P, Doddmani SS, Riyas M. To Study  
the Level of Awareness About Complications of Chronic Suppurative  
Otitis Media (CSOM) in CSOM Patients J Clin Diagn Res. 2014  
Feb;8(2):59-61.
25. Malkappa SK. Study of aerobic bacterial isolates and their antibiotic  
susceptibility pattern in chronic suppurative otitis media. Indian J Otol  
2012;18:136-9
26. Prayaga N. Srinivas Moorthy, Srikanth Kolloju, Srivalli Madhira, Ali  
Behman Jowkar. Clinical Study on Deviated Nasal Septum and its  
Associated Pathology. International Journal of Otolaryngology and  
Head & Neck Surgery, 2014, 3, 75-81 March 2014
27. **Gaur RS, Mathew J, Varghese AM, Mathew GA, Chandrasekharan ....**  
Monasta L, Ronfani L, Marchetti F, Montico M, Vecchi Brumatti L,

- Bavcar A, **et al.** Microbiological pattern of chronically discharging ears  
Indian Journal of Otology .April 2013 . Vol 19 Issue 2.
28. Wariso BA, Ibe SN. Bacteriology of chronic discharging ears in Port Harcourt, Nigeria. West Afr J Med 2006;25:219-22.
  29. Sabarinathan & Aaruna Rajkumari Int J Biol Med Res. 2015; 6(3): 5216-5218
  30. Gilleland LB, Gilleland HE, Gibson JA, Champlin FR. Adaptive resistance to aminoglycoside antibiotics in *Pseudomonas aeruginosa*. J Med Microbiol 1989;29:41–50
  31. Nikaido H. Multiple antibiotic resistance and efflux. Curr Opin Microbiol 1998;1:516–23.
  32. Poole K. Multidrug efflux pumps and antimicrobial resistance in *Pseudomonas aeruginosa* and related organisms. J Mol Microbiol Biotechnol 2001;3:255–64
  33. Zihra-Zarifı I, Llanes C, Kohler T, Pechere JC, Plesiat P. In vivo emergence of multidrug-resistant mutants of *Pseudomonas aeruginosa* overexpressing the active efflux system MexA-MexB-OprM. Antimicrob Agents Chemother 1999;43:287–91
  34. Akasaka T, Tanaka M, Yamaguchi A, Sato K. Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of *Pseudomonas aeruginosa* isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance. Antimicrob Agents Chemother 2001;45:2263–8
  35. Maria bălăsoiu, a.t. bălăsoiu, rodica mănescu, carmen avramescu, oana ionete. *Pseudomonas Aeruginosa* Resistance Phenotypes and Phenotypic Highlighting Methods. Current Health Sciences Journal. Vol. 40, No. 2, 2014 April June.

36. Nordman P., Poirel L. , Dortet L.. Rapid Detection of Carbapenemase-producing Enterobacteriaceae Emerg Infect Dis. Sep 2012; 18(9): 1503–1507.
  37. Sivaraman Umadevi, Noyal M Joseph, Kandha Kumari, Joshy M Easow, Shailesh Kumar.Detection of extended spectrum beta lactamases, ampc beta lactamases and metallobetalactamases in clinical isolates of ceftazidime resistant **Pseudomonas Aeruginosa**. Braz J Microbiol. 2011 Oct-Dec; 42(4): 1284–1288.
  38. MD, Çavuşlu Ş, Tuğrul HM. Investigation of Metallo Beta Lactamases and Oxacilinases in Carbapenem Resistant Acinetobacter baumannii Strains Isolated from Inpatients.. Balkan Med J. 2015 Jan; 32(1):79-83.
- 
39. Derek F. J. Brown Jenny Andrews, Anna King, Alasdair P. MacGowan. Detection of extended-spectrum  $\beta$ -lactamases with Etest and double-disc potentiation methods.Journal of antimicrobial chemotherapy. (2000), 46, 323-342.
  40. Behera B, Mathur P, Das A, Kapil A, Sharma V. An evaluation of four different phenotypic techniques for detection of metallo-beta-lactamase producing Pseudomonas aeruginosa.Indian J Med Microbiol. 2008 Jul-Sep;26(3):233-7.
  41. Berman S. Otitis media in developing countries. Pediatrics 1995;96:126.
  42. Rout MR, Mohanty D, Vijaylaxmi Y, Kamalesh B, Chakradhar M. Prevalence of cholesteatoma in chronic suppurative otitis media with central perforation. Indian J Otol 2012;18:7-10.
  43. Morris PS, Leach AJ. Prevention and management of chronic suppurative otitis media in aboriginal children: A practical approach. Comm Ear Hearing H 2007;4:22

44. Aslam MA, Ahmed Z, Azim R. Microbiology and drug sensitivity patterns of chronic suppurative otitis media. *J Coll Physicians Surg Pak* 2004;14:459-61.
45. Poorey VK, Lyer A. Study of bacterial flora in csom and its clinical significance. *Indian J Otolaryngol Head Neck Surg* 2002;54:91-5.
46. Morris PS, Leach AJ. Prevention and management of chronic suppurative otitis media in aboriginal children: A practical approach. *Comm Ear Hearing H* 2007;4:22-5.
47. Chakraborty A, Bhattacharjee A, Purkaystha P. Microbiological profile of chronic suppurative otitis media: Its significance in North-East India. *Indian J Otol* 2005;11:39-44.
48. Fatma AA, Assiry S, Siraj MZ. Microbiological evaluation and aspects on management of chronic suppurative otitis media in Riyadh. *Indian J Otol* 1998;4:115-20.
49. Goyal R, Aher A, De S, Kumar A. Chronic suppurative otitis media-A linico microbiological study. *Indian J Otol* 2009;15:18-22.
50. Hegde MC, Bhat GK, Sreedharan S, Ninan GP. Bacteriological study of tubotympanic type of chronic suppurative otitis media. *Indian J Otol* 2005;11:13-6.
51. Naheed P, Khan Z, Khan IM, Suhail AS, Zuber A. Bacteriological study of patients with discharging otitis media-A rural study. *Indian J Otol* 2003;9:29-32.
52. Kuchal V. Antibiotic sensitivity pattern in chronic suppurative otitis media (Tubotympani type) in Kumoun region. *Indian J Otol* 2010;16:17-21.

53. Shyamla R, Reddy SP. The study of bacteriological agents of chronic suppurative otitis media—aerobic culture and evaluation. *J Microbiol Biotechnol Res* 2012;2:152-62.
54. Kumar H, Seth S. Bacterial and fungal study of 100 cases of chronic suppurative otitis media. *J Clin Diagn Res* 2011;5:1224-7
55. Sen Gupta,R.P and Kacker,S.k.Otomycosis *Indian J Medical Sciences*,32;5-7
56. Urmil Mohan,Neeraj Jindal .Fungal and Bacterial flora in chronic suppurative otitis media in amrister,46;5-7.
57. Mansoor T, Musani MA, Khalid G, Kamal M. *Pseudomonas aeruginosa* in chronic suppurative otitis media: Sensitivity spectrum against various antibiotics in Karachi. *J Ayub Med Coll Abbottabad* 2009;21:120-3.
58. Gulati SK. Investigative profile in patients of chronic suppurative otitis media. *Indian J Otol* 1997;3:59-62.
59. Anupam M, Girish S, Devika N, Chandra MS. Bacteriological study of chronic suppurative otitis media. *Indian J Otol* 1999;5:87-91.
60. Lee SK, Lee MS, Jung SY, Byun JY, Park MS, Yeo SG. *Otolaryngol Head Neck Surg.* 2010 Oct; 143(4):500-5.
61. Mansoor T, Musani MA, Khalid G, Kamal M. *Pseudomonas aeruginosa* in chronic suppurative otitis media: Sensitivity spectrum against various antibiotics in Karachi. *J Ayub Med Coll Abbottabad.* 2009;21(2):120-3.
62. Sharma.S,Rehan HS,Afridi,AAK,Ejak A,Farooq S,ZaidiSK.. Bacteriological profile in Chronic Suppurative otitis media in eastern Nepal.*Trop Doct* 2004;34:102-4.
63. Saini S,Gupta N,Aparna Seema,Sachdeva OP.Bacteriological study of paediatric and adult chronic suppurative otitis media.*Indian J pathol Microbiology* 2005;48:413-6.

64. Wario BA,Ibe SN.Bacteriology of chronic discharging ears in Port Harcourt,Nigerai.West Afr J Med 2006;25:219-22.
65. T. Sabarinathan, V. Aruna Rajkumari. Bacteriological And Resistance Profile In Isolates Of Chronic Suppurative Otitis Media. Int J Biol Med Res.2015;6(3):5216-5218
66. Dr Aparna Chavan , \*\*Dr Rajhans Nagarkar, \*\*\*Dr GN Chavan , \*Dr PT Deshmukh. A study of microbiological spectrum with its antibiotic susceptibility in patients of chronic suppurative otitis media at RIMS, Adilabad. International J. of Healthcare and Biomedical Research, Volume: 03, Issue: 01, October 2014, Pages 152-157.
67. Picao, R.C.; Poirel, L.; Gales, A.C.; Nordmann, P. (2009). Diversity of beta-lactamases produced by ceftazidime-resistant *Pseudomonas aeruginosa* isolates causing bloodstream infections in Brazil. Antimicrob Agents Chemother. 53, 3908-3913.
68. Ettehad GH, Refahi S, Nemmati A, Pirzadeh A, Daryani A. Microbial and antimicrobial susceptibility patterns from patients with chronic otitis media in Ardebil. Int J Trop Med 2006;1:62-5
69. Singh AH, Basu R, Venkatesh A. Aerobic bacteriology of chronic suppurative otitis media in Rajahmundry. Biol Med 2012;4:73-9.
70. Aggarwal, R.; Chaudhary, U.; Bala, K. (2008). Detection of extended spectrum beta-lactamase in *Pseudomonas aeruginosa*. Indian J Pathol Microbiol. 51, 222-224
71. Picao, R.C.; Poirel, L.; Gales, A.C.; Nordmann, P. (2009). Diversity of beta-lactamases produced by ceftazidime-resistant *Pseudomonas aeruginosa* isolates causing bloodstream infections in Brazil. Antimicrob Agents Chemother. 53, 3908-3913.



72. Parveen, M.; Harish, B. N.; Parija, S. C. (2010). AmpC beta lactamases among gram negative clinical isolates from a tertiary hospital, South India. *Braz J Microbiol.* 41, 596-602.
  73. Lee K, Kim YA, Park YJ, Lee HS, Kim MY, Kim EC, et al. Increasing prevalence of vancomycin-resistant enterococci, and cefoxitin-, imipenem- and fluoroquinolone-resistant gram-negative bacilli: a KONSAR study in 2002. *Yonsei Med J.* 2004 Aug 31;45(4):598–608.
  74. Lee H, Yong D, Lee K, Hong SG, Kim EC, Jeong SH, et al. Antimicrobial resistance of clinically important bacteria isolated from 12 hospitals in Korea in 2004. *Korean J Clin Microbiol.* 2005 Apr;8(1):66–73.
  75. European centre for disease prevention and control(Internet).Available from : [http://ecdc.europa.eu/en/activities/diseaseprogrammes/ARHAI/Pages/public\\_consultation\\_clinical\\_microbiology\\_infection\\_article.aspx](http://ecdc.europa.eu/en/activities/diseaseprogrammes/ARHAI/Pages/public_consultation_clinical_microbiology_infection_article.aspx)
  76. Lee SK, Park DC, Kim MG, Boo SH, Choi YJ, Byun JY, Park MS, Yeo SG. Rate of isolation and trends of antimicrobial resistance of multidrug resistant pseudomonas aeruginosa from otorrhea in chronic suppurative otitis media. *Clin Exp Otorhinolaryngol.* 2012 Mar; 5(1):17-22. Epub 2012 Mar 22.
-